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If science teaches us anything, it teaches us to accept our failures, as well as our 
successes, with quiet dignity and grace. 
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SUMMARY 
Bone marrow is a complex, heterogeneous, primary immune tissue that is 
composed of distinct microenvironments. The stromal cells that make up these 
microenvironments regulate normal hematopoietic function and are instrumental in the 
tissue’s response during illness or therapeutic intervention. These stromal cells create the 
two primary niches in bone marrow: the endosteal and perivascular niches. While there are 
a sizeable number of examples of in vitro culture methods that recreate aspects of the bone 
marrow microenvironment using biomaterials, co-cultures, or ectopic implants, there are 
relatively few examples that recreate both the endosteal and perivascular niches in a single, 
defined culture. It is critical for both in vitro modeling of disease and furthering our 
understanding of the normal physiological processes of the bone marrow that we can 
recapitulate these basic structures of bone marrow together in a single platform. 
The overall goal of this dissertation was to create a multi-niche bone marrow mimic 
to study the role of the endosteal and perivascular niches in hematopoietic stem cell 
biology. In Aim 1, we designed, fabricated, and developed a microfluidic device, human 
bone marrow-on-a-chip (hBM-on-a-chip) that recreates the endosteal surface with adjacent 
microvasculature. In Aim 2, we assessed the utility of the hBM-on-a-chip as a platform for 
studying hematopoietic stem cell mobilization and the effects of radiation on the bone 
marrow microenvironment. The work presented in this dissertation provides tools for the 
in vitro study of human bone marrow, the hematopoietic system, and therapeutics that aim 
to alter its physiologic state.  
 
 1 
CHAPTER 1. INTRODUCTION* 
1.1 Overview 
 Hematopoietic stem cells (HSCs) are responsible for continuously populating the 
body’s blood and immune cells through the process of hematopoiesis. During early 
developmental stages, HSCs reside in the fetal liver and eventually move to the spleen and 
finally to the bone marrow (BM), where HSCs exist and hematopoiesis is ongoing in 
healthy adults [2]. Within the BM, specific signals from the local microenvironment (1) 
direct HSCs to maintain a multipotent population, (2) signal HSCs to differentiate into 
hematopoietic progenitor cells (HPCs), and (3) support differentiation into lineage 
restricted hematopoietic cells (B cells, T cells, natural killer cells, dendritic cells, 
neutrophils, macrophages, eosinophils, basophils, mast cells, megakaryocytes (MKs), and 
erythrocytes) to maintain homeostasis of blood and immune cells within the body. 
Replicating the intricacies of the HSC ‘niche’ in vitro is a complex task, but efforts toward 
this goal further our understanding of HSC physiology and can create useful preclinical 
models for understanding therapeutic effects in physiologically relevant culture systems. 
 The concept of an HSC ‘niche’ was first conceived by Schofield in 1978 [3] and 
our understanding of it has continued to evolve since. At first, the niche was largely 
believed to be endosteal, supported by cells on or near the inner lining of the bone [4-6]. 
More recently there have been several studies that have identified the HSC niche to be 
                                                 
*Adapted from [1] Nelson, M. R. & Roy, K. Bone-marrow mimicking biomaterial niches 
for studying hematopoietic stem and progenitor cells. J Mater Chem B 4, 3490-3503, 
doi:10.1039/c5tb02644j (2016). Reproduced by permission of the Royal Society of 
Chemistry.  
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perivascular, adjacent to the sinusoids and vasculature that permeate BM [7,8]. Regardless, 
it is evident that both the endosteal and perivascular niches play an important role in the 
maintenance of the hematopoietic system throughout adulthood. 
 There have been many efforts to replicate or mimic some or all the components of 
the hematopoietic niche in order to study hematopoietic stem and progenitor cells (HSPCs) 
or affect HSPCs toward a desired outcome using an in vitro culture. The first reports of 
HSC culture and differentiation in vitro, the Dexter culture [9], used a two-dimensional 
layer of BM stromal cells in the presence hydrocortisone and serum. Dexter cultures were 
able to sustain hematopoiesis, but without the addition of cytokines differentiation was 
lineage restricted [10]. Many cytokines have been used for the expansion of HSCs, 
including stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand, and interleukins (IL)-
6 and -11 [11]. Additionally, a number of stromal cell lines have been developed for co-
culture because they express high levels of cytokines that are specific to HSC expansion or 
that support differentiation of specific hematopoietic lineages [11]. Over the last twenty 
years, in vitro HSC cultures have moved beyond 2D co-cultures with cytokine stimulation 
and researchers have begun to use more complex biomaterial based systems that imitate a 
greater number of variables that are present within the HSC niche [12-18]. However, there 
are no examples of fully human, in vitro, BM cultures that contain both the endosteal and 
perivascular niches. 
 There are many potential applications for a human, in vitro BM culture model. In 
addition to the expansion and differentiation of HSCs for specific therapeutic needs, the 
culture system could serve as a platform to study both basic HSC biology and the effects 
of clinical intervention on HSCs and the BM microenvironment.  
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 Clinically, HSCs have been used to treat a range of blood related pathologies for 
over fifty years in BM transplantation [19]. Transplantation typically falls within two 
categories based on the source of the transplanted cellular material: allogeneic (donor tissue 
originating from someone other than the patient) or autologous (transplanted cells 
generated from healthy patient tissue). While the quantity of healthy allogeneic donor cells 
is typically enough, there are several problems associated with allogeneic transplantation, 
mainly the matching of donor and patient tissue to avoid rejection of implanted cells or 
development of graft-versus-host disease. Although autologous transplantation is preferred 
because it eliminates problems with compatibility of transplanted tissue, there are limited 
numbers of HSCs that can be harvested from a patient for transplantation and ex vivo 
expansion is necessary to achieve adequate numbers of cells for an effective dose. 
Transplantation of HSCs first requires collection of HSCs from the donor (the patient 
themselves in the case of autologous transplantation) and the preparation of the recipient 
tissue. To collect HSCs, typically the cells are mobilized from the BM compartment into 
peripheral blood so that they can be collected by leukapheresis. Second, any malignancy 
in the patient must be ablated, either by radiotherapy or chemotherapy, prior to 
transplantation, which will also deplete any remaining HSPCs. Then, previously harvested 
cells can be administered to reconstitute a healthy hematopoietic system. Preclinical 
approaches to studying HSC mobilization and engraftment are currently limited to animal 
models. 
 Because BM is responsible for ongoing hematopoiesis during adulthood, it is 
protected from natural sources of radiation by the bone it is encased within [20]. There are 
circumstances, both clinical and accidental, where people are exposed to high doses of 
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radiation and this can lead to failure of the hematopoietic system. Our understanding of 
radiation exposure is limited to animal models and patients from widespread exposures 
(e.g. Fukushima, Chernobyl). A defined in vitro model could allow us to further our 
understanding of the effects of radiation on the BM and the role that the microenvironment 
plays in alleviating or aggravating the resulting damage to the hematopoietic system.  
As with other simple in vitro models and more complex organ-on-chip 
technologies, there are potential applications for preclinical drug screening, especially in 
the context of anti-cancer therapeutics. Multiple myeloma (MM), leukemia, and other 
hematologic malignancies originate or reside within the BM compartment, and screening 
therapeutics (especially those that do not act directly on cancerous cells) in a BM specific 
microenvironment could increase the efficacy of preclinical testing. Testing of cellular 
therapies (like chimeric antigen receptor T cells) in complex environments is critical, 
because the tumor associated tissue can dramatically impact the activity of the therapeutic 
cells. Similarly, tissue specific culture models are important for preclinical testing of 
clinical interventions that specifically target the BM or BM resident cells. 
In addition to multipotent HSCs for the reconstitution of the hematopoietic system, 
there is also a clinical need for differentiated hematopoietic cells. There is a high and 
growing demand for blood [21] and platelets [22] for transfusion and due to stagnate donor 
pools and increasing costs, ex vivo expansion of therapeutic cells may be an alternative. 
Efficient ex vivo generation and expansion of therapeutic cells is necessary to realize the 
full clinical potential of HSCs and this requires in vitro culture systems that can replicate 
the complexities of the microenvironment within the BM and other hematopoietic niches.  
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1.2 Hypothesis 
 The overall hypothesis of this dissertation was that using a poly(dimethyl) sulfoxide 
(PDMS) microfluidic platform, the endosteal and perivascular niches of BM could be 
recapitulated in a physiologically relevant manner. The overall objective was to develop 
this platform and to assess the relevance in two preclinical applications. 
1.3 Specific aims 
1.3.1 Aim 1: Design, fabrication, and characterization of human bone marrow-on-a-
chip (hBM-on-a-chip) to mimic the human bone marrow microenvironment. 
 In the first aim, multiple iterations of design and characterization were performed 
to develop a microfluidic, organ-on-a-chip model of human BM that recapitulated basic 
characteristics of the endosteal and perivascular BM microenvironments. This was 
accomplished through two, interconnected sub-aims (Figure 1): 
A. Design a PDMS microfluidic platform, hBM-on-a-chip, and optimize the 
fabrication process. 
B. Characterize the bone marrow microenvironments and HSPC behavior in hBM-on-
a-chip. 
1.3.2 Aim 2: Use hBM-on-a-chip as a model system to study effects of therapeutics and 
disease on bone marrow. 
 In the second aim, the device designed and characterized in Aim 1 was evaluated 
for its ability to model BM physiology in two clinically relevant situations of BM 
perturbation: the mobilization of HSPCs from the BM niche and the irradiation of BM. 
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This was accomplished through two, distinct sub-aims (Figure 1): 
A. Study mobilization of HSPCs from hBM-on-a-chip and therapeutic effects on the 
bone marrow microenvironment. 









 In CHAPTER 2, we provide background information that details the BM 
microenvironment and previous work that has been done to recreate part of or all the HSC 
niche in vitro. In CHAPTER 3 the design and fabrication methods (Aim 1A) of hBM-on-
a-chip is presented and in CHAPTER 4 the characterization of hBM-on-a-chip (Aim 1B) 
is shown. CHAPTER 5 (Aim 2A) and CHAPTER 6 (Aim 2B) demonstrate the application 
of hBM-on-a-chip in HSC mobilization and BM radiation studies, respectively. Finally, in 
CHAPTER 7 conclusions from this work and potential future directions are discussed.  
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CHAPTER 2. BACKGROUND AND SIGNIFICANCE* 
2.1 Hematopoietic stem and progenitor cell niche in BM 
 BM is a densely populated, highly vascularized, and non-uniform environment 
(Figure 2). Although HSCs have been the most studied of adult stem cells, there still exists 
some uncertainty of the exact location and environment of the HSC niche within BM. Most 
studies to date of the HSC niche have used in vivo models. However, due to the relative 
scarcity of HSCs in BM (<0.005% of BM cells) [23] it is challenging to study niche 
characteristics in animal models. Similarly, studies of HPCs and differentiation are 
difficult, although not impossible, to track longitudinally in vivo. In 2009, Lo Celso et al. 
reported a technique for in vivo imaging of single hematopoietic cells from specific stem 
and progenitor populations using confocal and two-photon microscopy [24]. More 
recently, several studies have used whole marrow imaging techniques to identify, with 
more specificity, the niche characteristics of HSCs [25]. In vivo and in vitro approaches to 
studying the hematopoietic niche are complementary; while in vivo models have much 
greater physiological complexity, in vitro models are much easier to manipulate, control, 
and observe in real time. To design biomaterials and cultures for HSPC expansion and 
differentiation, the native microenvironment must be understood so that specific properties 
can be emulated to elicit natural behavior in vitro. 
 
 
                                                 
*Adapted from [1] Nelson, M. R. & Roy, K. Bone-marrow mimicking biomaterial niches 
for studying hematopoietic stem and progenitor cells. J Mater Chem B 4, 3490-3503, 




Figure 2. Cellular, biochemical, and physical characteristics of human bone marrow 
microenvironments [1]. BM can be divided into three distinct microenvironments: the 
endosteal niche, the central marrow, and the perivascular niche. Each of these 
microenvironments has different cellular constituents, ECM characteristics, biochemical 
signals, and physical properties that direct hematopoietic cell behavior. HSCs and 
hematopoietic progenitor cells occupy different niches within the BM and are instructed to 
maintain multipotency through senescence, to proliferate, or to differentiate by the signals 
in the occupied niche. Chemical gradients of Ca2+ and pO2 are established across the BM 
and are important to homing and proliferation of hematopoietic cells. 
 
 
2.1.1 Hematopoietic stem and progenitor cells (HSPCs) in BM 
 HSCs (human: Lin-CD34+CD38-CD90+; mouse: Lin-Sca1+cKit+ (LSK) CD34-) are 
multipotent, adult stem cells that can differentiate into all cell types in the hematopoietic 
lineage (Figure 3). The ability of HSCs to self-renew and reconstitute the hematopoietic 
system upon engraftment can either be categorized as long-term (LT-HSC) or short-term 
(ST-HSC), depending on the duration for which the HSC can self-renew and reconstitute 
 9 
the hematopoietic system. HSCs differentiate into multipotent progenitors (human: Lin-
CD34+CD38-CD90-; mouse: Lin-Sca1+cKit+CD34+) that can differentiate into all 
hematopoietic lineages but are incapable of self-renewal. Multipotent progenitors further 
differentiate into common myeloid progenitors (CMP) and common lymphoid progenitors 
(CLP) that are oligopotent and can differentiate into lineage restricted progenitors [26]. 
Lineage restricted progenitors can terminally differentiate into mature effector cells, 
although in many cases this process occurs outside of the BM in peripheral tissues. 
Collectively, HSCs, multipotent progenitors, oligopotent, and lineage restricted 




Figure 3. The differentiation of hematopoietic cells from HSCs [1]. LT-HSCs are 
capable of self-renewal and differentiation toward ST-HSCs and multi-potent progenitor 
cells. Multi-potent progenitor cells differentiate into common oligopotent progenitor cells 
for the myeloid and lymphoid lineages. Common myeloid and lymphoid progenitors 
differentiate into lineage restricted progenitor cells that can develop into mature effector 
cells, although the final steps of maturation often occur outside of the BM. Dotted lines 
indicate a series of lineage restricted progenitor cells. 
 
 
2.1.2 Multiple niches for HSPCs within BM 
 One challenge in understanding the HSC niche within BM is that it is unlikely that 
a single niche exists. Rather, recent findings have pointed towards multiple, distinct niches 
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existing within the BM that support different functions. There are three regions within the 
bone marrow that we can consider: (1) the endosteal niche, BM is contained within long 
bones and has a large surface area of contact with the inner, endosteal surface; (2) the 
perivascular niche, BM is highly vascularized with microvasculature and larger sinusoids; 
and (3) the central marrow, the densely populated, heterogeneous, cellular regions that exist 
between the sinusoids and the endosteal surface. Early research of the BM niche suggested 
that the endosteal surface and osteoblasts formed the HSC niche [6,27] and that calcium 
signaling was critical to engraftment of LT-HSCs [28]. However, recently the field has 
shifted and the current paradigm is that LT-HSCs reside in a perivascular niche [8] and are 
supported by perivascular stroma and endothelial cells. In addition, it is now thought that 
hematopoietic progenitors occupy distinct niches in the endosteal and central marrow 
spaces [7]. This change in paradigm highlights the relative uncertainty that remains in our 
current understanding of BM microenvironments [29-31]. Despite the new understanding 
of HSC niche location, the model of the BM niche is still incomplete and furthermore these 
microenvironments do not exist in isolation. For example, the vasculature in BM exists 
throughout the entire organ, meaning there are both perivascular niches that are distant 
from and adjacent to the endosteal surface. In certain niches, cells can inhabit two of these 
environments simultaneously. In vitro, biomaterial-based culture systems can provide a 
means to explore how the different properties of these microenvironments direct 
hematopoietic fate and function in isolation and in the context of one another. 
2.1.3 Many cell types interact with HSPCs in the BM niche  
 In addition to the numerous hematopoietic cells that occupy BM, many stromal 
cells exist within BM and have various roles in influencing the maintenance, proliferation, 
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and differentiation of HSCs. The endosteal niche is occupied by osteoblasts [32], which 
line the endosteal surface depositing extracellular matrix (ECM), and osteoclasts [32], 
macrophage derived cells responsible for bone resorption. HSCs in the perivascular niche 
interact with several cells, including endothelial cells, CXCL12 abundant reticular (CAR) 
cells, mesenchymal stromal cells (MSCs), and neurons. Sinusoidal endothelial cells [29,32] 
provide a barrier for entry to and exit from circulation and express cytokines that signal to 
HSCs [8]. CAR cells secrete the chemokine CXCL12 (or stromal derived factor-1 (SDF-
1)) that maintains hematopoietic cells in BM through binding of the CXCR4 surface 
receptor [33,34]. Nestin+ MSCs in mice were found to be spatially associated with HSCs 
near the vasculature, creating a dual, adult stem cell niche [35]. Recently, HSC behavior 
has been shown to also be influenced by neural signaling: nonmyelinating Schwann cells 
have been observed to influence HSC dormancy [36] and sympathetic nervous system 
signaling can control mobilization of HSCs [37]. The central marrow contains a number of 
hematopoietic cells, including macrophages, adipocytes, CAR cells, and fibroblasts [32]. 
The interactions between hematopoietic cells and the resident stromal cells within the 
central marrow are less understood.  
2.1.4 Extracellular matrix (ECM) in BM is spatially varying 
 The ECM in BM varies greatly between the different niches; collagen (COL) types 
I and IV [38,39], fibronectin (FN) [38,39], laminin (LN) [38-41], hyaluronic acid (HA) 
[38,42,43], heparin [38], osteopontin (OPN) [44-46], and several other ECM proteins [47] 
are present in BM. However, the ECM is not continuous throughout the different 
microenvironments. ECM in the stem cell niche is important for regulating cellular 
behavior. HSCs are typically considered non-adherent cells; however, they do have several 
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surface receptors that are capable of binding to ECM proteins and glycosaminoglycans 
(GAGs). ECM proteins and GAGs can also influence HSCs indirectly by providing unique 
environments for stromal cells and by immobilizing cytokines and chemokines. In the 
endosteal niche, osteoblasts create a distinctive ECM environment that is typical to bone 
matrix. Endosteal ECM contains collagens I and IV, OPN and FN [39,44]. The perivascular 
niche contains ECM that is typical to the basement membrane of endothelial cells, 
including collagen IV, LN, and FN [39,40]. The central marrow contains less ECM than 
the endosteal and perivascular niche, however FN, LN, HA, and heparin exist within the 
central marrow at low concentrations [38,39,43]. 
2.1.5 Biochemical signals in BM  
 To achieve maintenance, proliferation, and HSCs all within a relatively small 
environment, BM stromal cells signal through a milieu of soluble, membrane-bound, and 
ECM bound cytokines and chemokines. We will only briefly discuss a couple of these 
signals; a number of reviews have explored this topic in greater detail [31,47,48]. CXCL12, 
secreted by CAR, endothelial and other stromal cells, is a chemoattractant that is bound by 
cells that express CXCR4 on their surface. The CXCL12-CXCR4 chemokine axis is the 
primary mechanism by which HSPCs are recruited and maintained within BM. A key 
component of maintaining HSCs, SCF is expressed by endothelial cells and MSCs and is 
both secreted and presented to HSCs in a membrane bound form [31,47]. SCF promotes 
survival and proliferation and activates HSC integrins VLA-4 and VLA-5 and promotes 
adhesion of HSCs to stromal cells. Other membrane bound signaling proteins include the 
Notch ligands, Jagged-1 and Jagged-2, which promotes differentiation and proliferation, 
and is presented on the surface of osteoblasts [49]. 
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 Soluble molecules within the BM have also been found to effect HSC behavior [2]. 
There exists a Ca2+ gradient (higher concentration of Ca2+ at the endosteal surface) because 
of calcium deposition that occurs during bone matrix formation. HSCs can bind Ca2+ 
through a calcium-sensing receptor and it effects the ability of HSCs to engraft to the BM 
niche [28]. The concentration of oxygen has been implicated in maintaining HSC 
populations by limiting HSC metabolism in a hypoxic environment on the endosteal 
surface [49]. However, a recent study by Spencer et al showed that the endosteal surface 
is actually less hypoxic than perisinusoidal regions, although the oxygen tension in the 
bone marrow overall was found to be relatively low [50]. 
2.1.6 Physical characteristics of BM  
 Most of hematopoiesis and HSC maintenance occurs in the trabecular region of 
long bones. Trabecular, or cancellous, bone is characterized by a highly porous, lattice 
network of bone that is filled with marrow. The topography of the bone surface may be 
important for creating specific cellular behaviors. The mechanical properties of adult stem 
cell niches have been examined closely since Engler et al. demonstrated that the fate of 
MSCs is dependent on the stiffness of the surface on which they are grown [51]. The 
mechanical properties of the three BM niches are quite different and there is a range of 
material stiffness within BM [52]. The endosteal surface is stiff (>35 kPa) [53], the marrow 
sinusoids are structured but more compliant (2-10 kPa) [54,55], and the central marrow is 
very soft (~0.3 kPa) [56]. 
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2.2 Considerations for engineering the BM Niche 
 There are several variables that need to be considered when designing a biomimetic 
niche: the type of material (synthetic, natural), the physical properties of the material 
(stiffness), the topography of the material, the surface chemicals structure, and 
immobilization of specific ECM or cytokines [57-63]. Here we will discuss recent work 
that has shown how HSCs respond to these different variables in vitro.  
2.2.1 Physical properties 
2.2.1.1 Substrate stiffness 
 In 2010, Holst et al demonstrated that HSC behavior is dependent on substrate 
elasticity. HSPCs cultured ex vivo on tropoelastin, a highly elastic biomaterial, coated 
plates were able to expand two- to three- fold times more than HSPCs cultured on tissue 
culture polystyrene (TCPS) [64]. In addition, in 2009, Adamo et al showed that mouse 
embryonic hematopoiesis is enhanced by fluid shear stress [65]. These two findings, when 
taken together, suggest that hematopoietic cells are capable of sensing and responding to 
an environment’s physical characteristics.  
 Since this first evidence of substrate elasticity effect on HSC function, a range of 
different material stiffness have been tested and HSCs have been found to be responsive to 
a range of material stiffness that corresponds to the range of mechanical properties found 
within BM. Several biomaterial culture systems have been used to modulate the physical 
characteristics of the culture surface while maintaining biochemical function. Murine 
HSCs cultured on collagen functionalized poly(acrylamide) (PA) substrates were 
responsive to a range of substrate stiffness from ~0.1 kPa to ~200 kPa. HSPCs cultured on 
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a soft surface (0.0442 kPa) had greater viability than cells cultured on stiffer surfaces [66]. 
Similarly, CD34+ HSPCs cultured on FN functionalized, polyvinyl alcohol-co-itaconic 
acid-coated dishes with elasticity ranging from 12.2 kPa to 30.4 kPa were shown to expand 
1.4 times more than CD34+ HSPCs cultured on TCPS [67]. These two experiments indicate 
that proliferation and viability of HSCs are associated with softer culture surfaces. In 
contrast, migration of hematopoietic cells appears to be enhanced on stiffer substrates. 
CD34+ HSPCs cultured on polyethylene glycol diacrylate (PEGDA) hydrogels with 
surface stiffness corresponding to a higher range of stiffness (20 kPa to 38 kPa) migrated 
faster on the stiffer (38 kPa) surface, demonstrating that matrix elasticity within the 
endosteal niche may provide a signal for mobilization [68]. Interestingly, it appears 
hematopoietic cells are sensitive to small differences in substrate stiffness – even within 
the range found in the central marrow. A range of stiffness found within the central marrow 
was tested using collagen matrices with elasticity of 0.05 kPa, 0.2 kPa, and 0.8 kPa; murine 
LSK cells showed increased proliferation on the 50 Pa substrate and increased clonogenic 
maintenance on the 800 Pa substrate [69]. The physical properties of a substrate should be 
considered when designing a hematopoietic culture system. Whether to choose a relatively 
soft or stiff material depends entirely upon the desired outcome. 
2.2.1.2 Spatial Constraint 
 The effects of spatial constraints on HSCs culture have been tested to determine 
whether the pore size or surface topography of a material could affect the behavior of 
HSCs. Microcavities formed by PDMS have been used to isolate HSPCs in spatially 
constrained cultures. FN was immobilized on amino-silanized PDMS microcavities 
ranging from 15 µm to 80 µm in diameter. HSCs in smaller microcavities proliferated less 
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and thus maintained higher levels of multipotent marker expression than those in larger 
microcavities [70]. The mechanism through which microcavity size impacts cell behavior 
is unclear. One suggestion is that secreted soluble factors are concentrated in a smaller 
cavity, changing the biochemical environment of a cell. Another hypothesis is that the cells 
can physically sense or are impeded by the small size of the cavity during proliferation in 
culture. The state of differentiation can also affect a cells behavior in a microcavity. 
Repopulation experiments with lethally irradiated mice established that ST-HSCs were 
maintained better in single-cell sized microcavities, while LT-HSCs were maintained in 
small and large microcavities [71]. Spatial constraint may prove to be a powerful tool for 
maintaining potency of hematopoietic cells ex vivo.  
2.2.2 Functionalization 
2.2.2.1 Surface chemistry 
 The characteristics of the chemical groups on the surface of a biomaterial can 
directly interact with a cell through membrane proteins and they can also affect the binding 
and localization of soluble factors in media and secreted by cultured cells to the material 
surface. To test the effect of different chemical groups on HSC expansion, Chua et al 
cultured CD34+ HSPCs on a carboxylated, aminated, or hydroxylated poly(ether sulfone) 
(PES) nanofiber mesh. After 10 days of culture, human CD34+ HSCs cultured on 
hydroxylated or carboxylated PES nanofiber mesh showed little proliferation, while cells 
cultured on the aminated surface demonstrated expansion equal to TCPS with better 
maintenance of colony forming units (CFUs) [72]. The length of the aminated conjugate 
was also tested by inserting ethylene, butylene, or hexylene spacers. CD34+ HSCs showed 
greater expansion on ethylene and butylene spacers, while hexylene spacers enhanced 
 17 
preservation of CD34+ phenotype [73]. The effect of surface amine density was tested by 
creating PES nanofiber mesh with varying amine density. CD34+ cells had greater 
expansion on PES nanofiber mesh with higher amine densities [74]. The reason for specific 
enhancement in HSC culture on aminated surfaces may be due to surface absorption of 
SCF, which has an isoelectric point of 5.76 and is negatively charged at neutral pH. Overall, 
these studies suggest that HSPCs are highly sensitive to small changes in the chemistry of 
the local microenvironment. 
2.2.2.2 ECM and cytokine surface immobilization for HSC maintenance and expansion 
 Significant effort has gone into functionalizing biomaterial surfaces with proteins, 
GAGs, and cytokines because it has potential to replicate specific signals within the BM 
environment in a controlled and defined manner. There are a few examples of studies that 
have tested a panel of functionalized surfaces or have compared the effects of immobilized 
ECM or cytokines versus presentation in a soluble form. In 2007, Franke et al cultured 
CD133+ HPCs on a number of surface immobilized ECM components (FN, heparin, 
heparin sulfate, HA, tropocollagen I, co-fibrils of collagen I with heparin and collagen I 
with HA) [75]. High cell-matrix interactions were observed with FN, heparin, heparin 
sulfate, and the collagen I co-fibrils; insignificant adhesion and spreading was observed in 
tropocollagen I and HA cultures. In 2011, Celebi et al cultured CD34+ HSCs on TCPS 
coated with collagens I and IV, LN, FN, a mix of all four ECM proteins, and a mix of 
collagens IV, LN, and FN to replicate the basement membrane [76]. CD34+ HSCs exhibited 
relatively similar viability on all the single coated ECM surfaces, although it was observed 
that FN and LN favored differentiation to erythroid and MK progenitors, respectively. 
Interestingly, the ECM mix without collagen I showed decreased ability to support 
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expansion than the complete mixture of ECM proteins.  
 While studying panels of ECM coated surfaces has helped further our 
understanding of the role of ECM within BM microenvironments, FN has been the most 
used and remains the best ECM component for HSC expansion in vitro [77-80]. In 1998, 
Dao et al showed that FN coated TCPS was able to support CD34+ HSCs over 72 hours ex 
vivo and sustain LT-HSC populations better than a stromal layer [78]. Similarly, Bhatia et 
al in 2002 compared CD34+ HSC culture with stromal support and on three different 
integrin binding FN fragments over 7 days and found that culture on FN fragments 
improved preservation of progenitor potential [79]. Jiang et al further explored the effect 
of different integrin binding FN domains by culturing CD34+ HSCs on two integrin binding 
FN domains, the CS-1 binding motif (EILDVPST) and RGD motif (GRGDSPC) [77]. 
Total cell expansion was not increased on CS-1 and RGD functionalized surfaces, however 
the expansion of CD34+ HSCs was significantly increased in cultures with the two 
fibronectin fragments, with CS-1 coated surfaces producing the greatest CD34+ HSC fold 
expansion. Based on these findings, it is believed that HSPCs can bind FN through VLA-
4 and VLA-5 integrin, which bind CS-1 and RGD, respectively, and this can impact 
expansion and maintenance of the cells in in vitro cultures.  
 For presentation of ECM and cytokines, covalent conjugation on the culture surface 
has many advantages over presentation in a soluble form. From a cost perspective, covalent 
immobilization generally requires less material to affect cells than soluble presentation or 
surface absorption because local concentrations at the culture surface are elevated. For 
ECM components, covalent conjugation of FN and collagen I on PET mesh resulted in 
100-fold and 73-fold expansion, respectively, of CD34+ cells after 10 days; however, 
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soluble FN resulted in a 10-fold expansion and surface absorbed FN induced only 2-fold 
expansion [77]. Immobilization of cytokines has shown mixed ability to effect HSPCs with 
similar efficacy as their soluble forms. When RGD and SCF or CXCL12 mixtures were 
covalently attached to a PEGDA hydrogel, 32D myeloid progenitors expanded equally in 
the presence of covalently immobilized or soluble SCF. However, migration of 32D cells 
was significantly increased in the presence of soluble CXCL12 when compared to the 
surface conjugated form [81]. Functional ECM motifs are typically bound within large 
networks of ECM proteins and GAGs in the extracellular space and accordingly the 
covalent conjugation of these components to culture surfaces results in increased biological 
activity because it likely recreates a more biologically relevant environment. However, 
cytokines and chemokines can be soluble, membrane bound, or bound to ECM and 
consequently the context of presentation of these proteins is important to the capacity to 
elicit a biological response. While SCF can be soluble, it is also presented in a surface-
bound form within BM microenvironments and this could explain why surface conjugated 
SCF is able to produce a strong biological response.  
2.2.2.3 ECM components have unique effects on hematopoiesis 
 The ability of ECM components to support in vitro generation of hematopoietic 
progenitors from HSCs under differentiation conditions has been tested by a number of 
groups [82-87]. For erythropoiesis (the development of red blood cells), LN has been 
shown to support CD34+ HSC differentiation toward erythrocytes while FN inhibited the 
process in an MSC co-culture [82]. For the differentiation of MKs, collagen and LN 
provide poor surfaces for attachment of megakaryocytic-erythroid progenitors, however 
FN allows for attachment [83], increases expansion and maturation [84], and promotes 
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proplatelet formation [85,86]. The difference in ECM ability to support different 
differentiation pathways underscores the concept of multiple BM niches; separate 
hematopoietic processes may occur under different microenvironment conditions and 
biomaterial cultures must be tailored to specific processes and outcomes. 
2.3 Examples of biomaterials for in vitro BM niche engineering 
 Several fabrication techniques have been used to create 3D environments with 
differing qualities for HSPC culture. Culture platforms have varied from porous scaffolds 
(scaffolds with pores large enough for cell penetration that represent truly 3D culture), 
nanofiber scaffolds (fibrous scaffolds with small pore sizes that form a 3D surface, but 
cells do not penetrate the scaffold), and hydrogels (a polymeric network that encapsulates 
the cells).  
2.3.1 Porous scaffolds 
 Various materials have been used to create porous scaffolds that mimic the 
architecture of trabecular bone. With large pore sizes, these scaffolds allow for cellular 
penetration so that the cells are cultured in a truly 3D environment. In 1992, Wang et al 
reported that collagen microspheres, 500-600 µm in diameter and with 20-40 µm pores, in 
a perfusion bioreactor supported hematopoiesis for up to 4 months with a continuous output 
of hematopoietic cells [10]. Tantalum coated porous biomaterials (TCPB), ~300 µm pore 
size, have been reported to support hematopoiesis in a number of culture conditions [88-
91]. CD34+ HSCs have been cultured on TCPB (with and without a coating of FN) in the 
absence of exogenous cytokines and have shown to have greater expansion than standard 
BM stromal co-culture [88-91]. TCPB does not have an active biochemical interaction with 
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cultured hematopoietic cells; the reason for improvement in culture outcomes is attributed 
to the 3D nature of the culture alone. Numerous porous scaffolds have been used for HSC 
expansion; these culture systems have generally depended on improved culture conditions 
of 3D environment compared to 2D culture systems to generate improved expansion and 
maintenance of HSCs, rather than specific functionalization or replication of niche 
components. To further replicate the BM niche, stromal co-culture has been employed to 
directly fulfill stromal signals from the niche. Designing biomaterial-based culture systems 
for HSC/stroma co-culture requires the surface of the material to have functionality that 
permits cell adhesion and growth for the stromal layer.  
2.3.1.1 Synthetic materials used for porous scaffolds 
 Except for TCPB, most porous scaffolds have been used to facilitate co-culture of 
hematopoietic cells with various stromal cells. Nylon [92], borosilicate glass [93], PCL 
[94], PLGA [94,95], PA inverted colloidal crystal (ICC) [96-98], and PET [99] are some 
examples of synthetic materials that have been used to support co-culture. These materials 
have varying pore sizes and surface chemistries that affect the 3D architecture of the culture 
and the adhesion (and therefore phenotype) of the supporting stromal cells. Differences 
associated with different surface chemistries of the materials are negligible, as most of the 
scaffolds are coated or functionalized with an ECM protein or to promote adhesion of the 
stromal cells. Interestingly, in 2003 Sasaki et al assessed the phenotypic differences 
between murine ST2 stromal cells cultured on a 2D surface and on a polyester nonwoven 
fabric disk. The authors found no difference in secreted factors (SCF, TPO), but found a 
significant increase in ECM deposition in the 3D culture [100]. This is the clear advantage 
of using a 3D porous scaffold in a co-culture system.  
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2.3.1.2 Natural materials used for porous scaffolds 
 Natural materials used to create porous scaffolds are typically those that are found 
in bone. Hydroxyapatite [101], collagen [94], and ‘bio-derived bone’ [102] HSC/stroma 
co-culture and have various efficacies that all show improvement over 2D co-culture 
systems. Hydroxyapatite and ‘bio-derived bone’ cancellous bone porous scaffolds are the 
most complete models of the ECM and biochemical environment found in the endosteal 
niche. Both materials contain calcium and are the only materials discussed here that can 
establish a gradient of Ca2+ within a culture. Although natural biomaterial porous scaffolds 
have desirable biochemical properties, they are not as easy to manipulate as synthetic 
materials with regards to modulating physical characteristics (elasticity, pore size) and 
functionalization. 
 Recently, decellularized bone has been used as a scaffold for a vascularized BM 
mimic using a microfluidic perfusion system [103]. ECs and MSCs were co-cultured in the 
bone matrix and when cultured under physiologically relevant interstitial flow conditions 
formed tubule structures in the porous space between the decellularized trabecular bone. 
This is one of the few examples of BM vascular niche engineering in the context of bone, 
although the bone matrix itself did not contain OBs. 
2.3.2 Nanofiber scaffolds  
 Nanofiber scaffolds have been fabricated using various materials, typically by 
using electrospinning to deposit the material in a uniform, fibrous mesh. There is limited 
evidence of cell penetration to within electrospun scaffolds because of small pore sizes 
within the mesh networks. Culture on nanofiber scaffolds is therefore not a truly 3D 
environment, although the ‘pseudo’ 3D environment that is created has been widely shown 
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to improve upon standard 2D cultures. Several synthetic polymers, including PCL [104], 
PES [72-74], PET [77], PLGA [94,105], polyester [100,106-108], and PU [109] have been 
reported to support HSC expansion with or without stromal co-culture. Because synthetic 
nanofiber scaffolds can be fabricated from a range of materials, with different physical 
characteristics (fiber size, fiber stiffness), that can be chemically modified to change the 
biological activity of the scaffold, nanofiber scaffolds are an incredibly useful platform for 
testing and developing unique engineering BM niches. The incorporation of natural 
materials into nanofibers for hematopoietic cell culture has been less widely reported [110]. 
Because nanofiber scaffolds are not truly 3D, they have limited ability to mimic the macro 
structures of trabecular bone (which may or may not be important to recreating the BM 
niche). The ‘pseudo’ 3D structure can also be a positive; because cells do not enter the 
scaffold, retrieval of cells for analysis or harvest is much easier. Recently, Batnyam et al 
demonstrated that PU nanofiber scaffolds seeded with human BM MSCs and CB CD34+ 
cells could be layered to create a 3D structure. HSPCs cultured in the layered nanofiber 
structure had similar expansion to a single layer of PU nanofiber culture, however the 3D 
layered structure had significantly higher colony forming potential [109].  
2.3.3  Hydrogels  
 An alternative to solid scaffold architecture, hydrogels are mechanically softer and 
can be constructed from natural materials that are found in the BM; hydrogels offer a useful 
platform for study of the BM niche, especially the central marrow. Alginate [111], collagen 
[69], FN [94], gelatin methacrylate [112], and HA [113] have been used to create hydrogels 
for the encapsulation of HSCs or differentiation of hematopoietic cells. The biological 
activity of cultured cells is dependent on the hydrogel material and the mechanical 
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properties of the hydrogels. The hydrogel material is important because they are bioactive 
and can recreate signals like the ECM microenvironments in BM, without obligatory 
stromal support. However, stromal co-culture provides many signals that improve cell 
phenotype in vitro. Chitteti et al demonstrated that co-culture of calvarial osteoblasts with 
LSK cells significantly increased expansion and maintenance potency (Lin-SCA1+) when 
compared to LSK cells cultured alone in collagen hydrogels across a range of hydrogel 
stiffnesses [69]. Most hydrogel systems that have been reported have been constructed 
using a uniform, single structural component, despite that BM ECM is complex and 
consists of multiple proteins and GAGs in each microenvironment. Hydrogels have been 
layered using photopatterning to create composite RGD functionalized PEGDA hydrogels 
that contained different stromal cells in order to model the bone marrow microenvironment 
[114]. Mahadik et al recently showed that a microfluidic device can be used to generate a 
gradient hydrogel, with spatially varying concentrations of cells, ECM components, or 
ECM bound cytokines [115]. These complex approaches to hydrogel construction, that 
create hydrogels composed of multiple ECM components in a spatially organized manner 
may be useful for more accurately replicating BM microenvironments in vitro.  
2.4 Effect of hydrogel stiffness on encapsulated MSCs* 
Prior to starting the main body of work in this dissertation, a study was performed 
that examined the effect of hyaluronic acid hydrogel stiffness on the phenotype of MSCs. 
                                                 
*Adapted from Nelson, M. R., Mejías, J. C., & Roy, K. Low stiffness hyaluronic acid-
poly(ethylene glycol) hydrogels increase expression of hematopoietic niche specific 
factors by human mesenchymal stem cells. In preparation. 
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2.4.1 Introduction 
 Mesenchymal stromal cells (MSCs) are found in the bone marrow where they are 
a part of the stromal microenvironment. Not only are MSCs capable of differentiation into 
other stromal cells, including osteoblasts and adipocytes [116], MSCs actively support the 
hematopoietic niche and secrete a number of cytokines that direct the fate of hematopoietic 
stem cells (HSCs) and hematopoietic progenitor cells (HPCs) [8,117]. MSCs express 
cytokines related to HSC maintenance, including stem cell factor (SCF) (both in soluble 
and membrane bound forms), and CXCL12 [118,119]. As well, MSCs express cytokines 
associated with hematopoietic differentiation, including IL-6, which is a key signaling 
cytokine during B lymphopoiesis [118]. MSCs have been widely used as supporting cells 
for recapitulating and controlling hematopoiesis in in vitro co-culture; both in 2D co-
culture systems and in 3D co-cultures on both solid scaffolds and in hydrogels [11,16,18]. 
Understanding how MSC phenotype changes with the properties of these culture platforms 
is essential for designing in vitro biomaterial based culture platforms that recreate the bone 
marrow microenvironment. 
 The extracellular matrix (ECM) in the bone marrow is spatially organized and is a 
key component in the regulation of hematopoietic function. Fibronectin, collagen, laminin, 
and hyaluronic acid (HA) have all been identified as important components of bone marrow 
ECM [39]. HA is an anionic, non-sulfated glycosaminoglycan that in tandem with 
CXCL12 signaling, plays an important role in the engraftment of HSCs to BM, through 
binding of surface expressed CD44 [120]. MSC phenotype as a function of interaction with 
protein components of ECM (fibronectin, collagen) has been characterized in in vitro 
cultures [121-123], comparatively less work has been done exploring how HA-CD44 
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interactions effect MSC phenotype. HA has been used extensively to create hydrogels for 
the encapsulation of MSCs for the purpose of differentiation [124,125]. MSCs can migrate 
on HA surfaces through CD44 binding of the glycosaminoglycan [126], however migration 
and proliferation are greatly increased through the introduction of RGD peptides [127].  
 It is well known that the phenotype of MSCs is dependent on the mechanical 
environment [51]. In the bone marrow, there are distinct microenvironments that have 
different mechanical properties. The endosteal surface is stiff (~ 35 kPa) [53], the marrow 
sinusoids are relatively compliant (5-20 kPa) [54], and the central marrow space is much 
softer ranging from 0.1 to 1 kPa [56]. There are several studies showing that over a large 
range of surface stiffness, MSCs exhibit different differentiation and secretory properties 
[51,128]. Less is known about how MSCs respond to changes in the mechanical 
environment on the scale that is observed within bone marrow. Recent work has shown 
that osteoblasts cultured on 800 Pa collagen surfaces had improved ability to support 
proliferation and maintenance of Lin-Sca-1+c-Kit+ (LSK) cell than those cultured on a 50 
Pa surface [69]. However, there is little work examining how MSC phenotype, with regards 
to establishing the HSCs niche, responds to environments within this mechanical range. 
 Here, we show that MSCs encapsulated in HA hydrogels respond to differences in 
mechanical properties that correspond to the range that has been measured for the central 
marrow. This work has implications for designing biomaterial systems for studying the role 
of MSCs in the bone marrow microenvironment and for creating culture systems for the 




2.4.2.1 Cell culture 
 Human MSCs (RoosterBio) were initially expanded in hMSC High Performance 
Media Kit (RoosterBio). After initial expansion, MSCS were verified by flow cytometry 
to be CD34-, CD45-, CD73+, CD90+, and CD105+. For subsequent passages, MSCs were 
cultured in αMEM (Sigma Aldrich) supplemented with 10% FBS (Hyclone) and 1% 
Penicillin-Streptomycin (Hyclone). MSCs were cultured at 37 °C and 5% CO2. For all 
experiments, MSCs were used at passage 3.  
2.4.2.2 HA-PEGDA hydrogel encapsulation 
 For encapsulation in HA-PEGDA hydrogels, passage 3 MSCs were resuspended in 
10 mg/mL HA-thiol (Glycosil, ESI BIO) at a density of 1x106 cells/mL. The HA-thiol cell 
suspension was mixed 4:1 with 1%, 2%, or 4% (w/v) 3400 Da PEG-DA (Extralink, ESI 
BIO) to make hydrogels with final concentrations of 0.8% w/v HA and 0.2%, 0.4%, or 
0.8% PEGDA. 50 µL of unpolymerized hydrogel cell suspension were transferred to 
modified 1 mL syringes [129] and hydrogels polymerized over ~30 minutes at room 
temperature. After polymerization, hydrogels were transferred to a 48-well plate and were 
cultured at 37 ºC, 5% CO2 with 1 mL αMEM (Sigma Aldrich) supplemented with 10% 
FBS (Hyclone) and 1% Penicillin-Streptomycin (Hyclone). Media was exchanged on days 
1, 4, 7, and 10. 
2.4.2.3 Rheometry 
 Hydrogel storage and loss moduli was measured by dynamic oscillatory strain and 
frequency sweeps using an MCR 302 Rheometer (Anton Paar) with a 9 mm diameter 2° 
cone and plate geometry. Hydrogels were synthesized, allowed to swell in PBS overnight, 
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and then loaded between the cone and plate. One gel per group was used to determine the 
linear viscoelastic range of the hydrogel using a strain amplitude sweep with angular 
frequency of 10 rad/s; strain from the linear portion was then used for the oscillatory 
frequency sweeps. Frequency sweeps were run with constant strain with ω = 0.1-100 rad/s. 
2.4.2.4 MSC viability 
 Hydrogels were washed with PBS and stained with calcein AM and ethidium 
homodimer III (EthD-III) (Biotium). Stained hydrogels were imaged on a spinning disk 
confocal microscope (Perkin Elmer). The number of live and dead cells were counted using 
ImageJ software [130,131] and the percentage of live cells was calculated by dividing 
number of calcein AM positive cells by the total (calcein AM and EthD-III) positive cells. 
2.4.2.5 Immunohistochemistry 
 Hydrogels were collected after 10 days culture. Hydrogels were washed with PBS 
and fixed with 4% paraformaldehyde (ThermoFisher) for 30 minutes. Hydrogels were 
washed again with PBS and suspended in OCT overnight at 4 ºC before being snap frozen 
in OCT and stored at -80 ºC.[132] The hydrogels were cut into 20 µm sections using a 
cryostat (Leica). Sections were blocked (1% goat serum, 0.05% Tween-20 in PBS), stained 
with rabbit anti-SCF (ab64677, Abcam) overnight at 4 ºC, washed with blocking buffer, 
and then stained with goat anti-rabbit-AF647 (ThermoFisher). Sections were mounted 
using Prolong Gold with 4',6-diamidino-2-phenylindole (DAPI) (Life Technologies). 
Stained hydrogel sections were imaged using a spinning disk confocal microscope (Perkin 
Elmer). Images were analyzed using Volocity software and representative images were 




 Supernatants were collected at 1, 4, 7, and 10 days; and stored at -80 ºC until 
analysis. Standard enzyme-linked immunosorbent assays (ELISA) were performed 
according to the manufacturer’s protocol to detect CXCL12α (SDF-1α), SCF, and IL-6 
(Peprotech). Uncultured media samples were used to correct for background in absorbance; 
absorbance values lesser or equal to background correction are reported as zero values. 
2.4.2.7 Statistical analysis 
 All data in the text are presented as mean ± SEM. Sample numbers are indicated in 
figure captions. Data were analyzed using GraphPad Prism software. Between group 
comparisons were performed using two-way analysis of variance (ANOVA) followed by 





Figure 4. Varying the mechanical properties of HA-PEGDA hydrogels. (A) Hydrogels 
were made with 0.8% (w/v) hyaluronic acid (HA) and 0.2%, 0.4%, or 0.8% (w/v) 
poly(ethylene glycol) diacrylate (PEGDA). (B) Storage (G’) and loss (G’’) moduli of the 
three HA-PEGDA hydrogel compositions measured by dynamic oscillatory rheological 
testing. Data are shown as mean ± SEM (n = 13, 11, 10 hydrogels for 0.2%, 0.4%, 0.8% 
PEGDA, respectively). Data analyzed using one-way ANOVA with Tukey’s multiple 




 Human MSCs (hMSCs) were encapsulated in HA-PEGDA hydrogels and cultured 
for a period of 10 days (Figure 5). Viability of the MSCs in the three HA-PEGDA hydrogel 
compositions was measured to be >90% after 1 day, indicating that there was not 
significant loss in viability during the hydrogel encapsulation process (Figure 5B). 
Viability of MSCs declined to between 74% and 78% by day 4. However, viability of the 
cells was relatively stable up to day 10, when viability was measured to be between 65% 
and 78% for the three PEGDA concentrations. At day 10, MSCs encapsulated in 0.4% 
PEGDA w/v hydrogels were measured to have slightly lower viability (65.4% live cells) 
than the 0.2% w/v and 0.8% w/v hydrogels (78.1% and 77.6%, respectively) (Figure 5A). 
However, there did not appear to be any trend in increased or decreased viability of MSCs 
associated with the mechanical properties or concentration of PEGDA of the hydrogels. 
 To explore the effects of the mechanical properties of the HA-PEGDA hydrogels 
on functional MSC phenotype, we measured MSC expression of both surface-presented 
and soluble cytokines after culture in the three different HA-PEGDA hydrogels. After 10 
days of culture, MSCs encapsulated in HA-PEGDA hydrogels were fixed and embedded 
for cryosectioning. Staining of hydrogel sections for SCF showed higher levels of 
expression in 0.2% PEGDA w/v hydrogels when compared to 0.4% w/v and 0.8% w/v 
PEGDA hydrogels (Figure 6A and 6Bi). While the average MFI of cells encapsulated in 
0.2% PEGDA hydrogels was significantly higher than 0.4% w/v (p < 0.05) and 0.8% w/v 
(p < 0.01), when individual cells are analyzed it reveals a large amount of heterogeneity in 
the encapsulated MSC population (Figure 6Bii). While many cells exhibit similarly low 
levels of SCF expression in all three hydrogels, there are increasing numbers of MSCs with 
high expression levels of SCF at lower PEGDA concentrations.  
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Figure 5. Viability of MSCs encapsulated in HA-PEGDA hydrogels. MSCs 
encapsulated in HA-PEG hydrogels were stained with calcein AM (live) and EthD-III 
(dead) to quantify the number of viable MSCs in the hydrogels at 1, 4, 7 and 10 days. Data 
are shown as mean ± SEM (n = 6 hydrogels). Data are analyzed using two-way ANOVA 





Figure 6. MSCs surface expression of SCF when encapsulated in HA-PEGDA 
hydrogels. (A) Representative fluorescence microscopy of SCF (red) and DAPI (white) of 
MSCs encapsulated in HA-PEGDA hydrogels. (B) Quantification of average MFI of SCF 
staining. Data are shown as mean ± SEM (n = 3 hydrogels). Data are analyzed using one-
way ANOVA with Tukey’s multiple comparisons test. *p < 0.05. **p < 0.01. (C) 
Quantification of SCF staining MFI of individual cells shown in (B). Data are shown as 




Figure 7. Secretion of cytokines by MSCs encapsulated in HA-PEGDA hydrogels.(A) 
IL-6, (B) SCF, and (C) CXCL12 detected by ELISA in hydrogel culture media on days 4, 
7, and 10. Data are shown as mean ± SEM (n = 5 hydrogels). Data are analyzed using one-
way ANOVA with Tukey’s multiple comparisons test. *p < 0.05. **p < 0.01. ***p < 0.001. 
****p < 0.0001. 
 
 
 Supernatants collected at days 4, 7 and 10 were analyzed by ELISA to determine 
relative secretion of cytokines relevant to signaling to hematopoietic cells. Overall, low 
levels of cytokines were detected in supernatant; all three cytokines measured were near 
the lower limit of the standard curve and therefore reliable concentrations cannot be 
reported. However, cytokines were detected above background (of uncultured media 
control) and the background corrected absorbance (450 nm) as measured by ELISA is 
reported. MSCs encapsulated in lower percentage PEGDA hydrogels secreted higher 
concentrations of IL-6 (Figure 7A), SCF (Figure 7B), and CXCL12 (Figure 7C) than MSCs 
secreted in higher percentage PEGDA hydrogels. Additionally, IL-6 and CXCL12 
secretion increased in 0.2% PEGDA/0.8% HA hydrogels from day 4 to day 10, conversely 
SCF secretion decreased over the same time period. 
2.4.4 Discussion 
 The bone marrow microenvironment has non-uniform mechanical properties and 
accurately modeling the biomechanical niche is important for in vitro modeling of the 
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microenvironment [53,54,56]. While the effect of surface mechanics has been studied 
across a wide range of surface stiffnesses, relatively less work has been done testing the 
effect of surface stiffness on the narrow range that is found in the bone marrow 
microenvironment. Here we have demonstrated that MSC cytokine expression is variable 
within a narrow, physiologically relevant mechanical range. 
 The phenotype of MSCs has been shown to be dependent on signals through 
binding of ECM and the mechanical properties of the local microenvironment [51,128]. 
The focus of much of the previous work in the field has been on how these factors 
contribute to the differentiation potential of MSCs; however, we believe that they can also 
contribute to a MSCs ability to act as a stromal cell in the hematopoietic microenvironment. 
To our knowledge, there are no studies evaluating MSC cytokine expression within this 
range of mechanical properties. 
 Using HA-PEGDA hydrogels, we were able to create hydrogels with elastic 
mechanical properties from ~50 Pa to ~350 Pa by varying cross-linker density and without 
changing the concentration of HA. These hydrogels fit within the previously reported range 
of the elastic modulus for the central marrow region of bone marrow (0.1-1 kPa) [56]. Even 
within a relatively narrow range of elastic moduli, we found that MSCs had increased 
expression of hematopoietic niche specific factors in ~50 Pa hydrogels relative to stiffer, 
~350 Pa hydrogels. SCF, a surface bound and soluble cytokine responsible for maintaining 
HSC potency [5,48,133], was expressed more in both forms by MSCs encapsulated in the 
lower modulus hydrogels. We also measured the secretion of two soluble factors, CXCL12 
(or stromal derived factor 1 (SDF1)), a chemokine responsible for maintaining the 
hematopoietic cells in the bone marrow [34,117], and IL-6, a cytokine responsible for both 
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the formation of osteoclasts and B cells in bone marrow [134,135]. These findings are 
complementary to recently reported work that showed osteoblasts supported increased 
LSK expansion when encapsulated in mechanically stiffer collagen gels within a similar 
range [69]. This suggests that MSCs and their stromal progeny have differing responses to 
mechanical stimuli and could serve similar functions in different niches within the bone 
marrow. 
 It is worth noting that MSCs do not interact with single ECM components in 
isolation. It is well reported that the density of RGD binding sites within a material can 
impact the proliferation and migration behavior of MSCs [127]. In order to fully understand 
the influence of ECM and mechanical stimuli on stromal cell behavior, more complex 
hydrogels and scaffolds must be used that recreate a the milieu of ECM in the bone marrow 
microenvironment [136]. 
2.4.5 Conclusions 
 In this work, we evaluated the effect of PEGDA crosslinker concentration and 
mechanical stiffness on MSC cytokine secretion when cultured in HA-PEGDA hydrogels. 
By varying the PEGDA concentration, we created HA-PEGDA hydrogels with a range of 
mechanical properties similar to the central marrow region of bone marrow. MSCs 
encapsulated in low PEGDA percentage (and low modulus) hydrogels, expressed more 
surface bound SCF and secreted more soluble IL-6, SCF, and CXCL12. These results 
suggest that MSCs are responsive to small differences in mechanical properties and that 
mechanical properties of in vitro hematopoietic niche or bone marrow cultures may be fine-
tuned to illicit desired phenotypes of stromal cells.  
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2.5 In vitro differentiation of HSPCs 
 Differentiation of mature hematopoietic cells from HSPCs has traditionally 
required large amounts of cytokine supplementation or very specific stromal cell support 
and the yet these cultures have typically had relatively low yield. Biomaterial approaches 
for differentiation may allow for 3D cultures with greater culture surface area for cell 
growth that could reduce the cost of cytokine addition, the functionalization of materials 
to increase the efficiency of signaling to cultured cells, and the creation of physical 
environments that are essential to the desired phenotype. Early ex vivo differentiation work 
used porous scaffold to test for improved efficacy over traditional 2D cultures. Using a 
relatively simple packed-bed reactor of macroporous collagen microspheres, low 
concentrations of erythropoietin were able to sustain erythropoiesis in BM cultures over 
several weeks [137]. Long-term erythropoiesis has been achieved using a 3D hollow fiber 
reactor with minimal input of exogenous cytokines [138]. This approach created a 
heterogeneous and diverse BM-like microenvironment of stromal and hematopoietic cells 
that supported physiologically relevant cell densities and ongoing production of 
erythrocytes. Differentiation of adaptive immune system cells (T and B cells) has been 
achieved in porous scaffold co-culture systems with differentiation specific cytokine 
addition. Using a PA ICC scaffold, co-culture of BM stroma and CD34+ HSCs produced 
mature B-lymphocytes after 14 days [96]. In a TCPB co-culture with murine thymic 
stroma, Poznansky et al were able to generate 70% CD3+ T cells from CD34+ progenitors 
and improve yield over a monolayer co-culture by 3-fold [139]. Stromal contact is not 
necessary for lymphocyte differentiation and the signals can be replaced by functionalized 
material surfaces. Previous research by our group has shown that immobilization of Notch 
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ligands on magnetic microbeads or TCPS can replace direct stromal contact for the in vitro 
differentiation of LSK [140] or CD34+ HSCs [141] to T lymphocytes. 
 Many materials-based systems have been designed for the differentiation of MKs 
for platelet production. 3D woven polyester fabric, PA ICC scaffold [97], aminated PES 
nanofiber [142], and pullulan/dextran hydrogel [143] cultures have all been used for CD34+ 
HSC differentiation to MKs and supported the production of platelets over days and weeks 
of culture. One of the more complete spatial models of BM has been designed for the 
culture of MKs for sustained production of platelets. In 2011, the Balduini lab reported the 
development of a culture system composed of a collagen I gel that surrounds a silk micro-
tube (marrow sinusoids) perfused with media [144]. Porous silk micro-tubes were prepared 
by dipping stainless steel wire into silk fibroin solutions containing poly(ethylene oxide) 
and then coated with various ECM proteins. In 2015, they further reported creating 
endothelialized silk micro-tubes in a similar manner [145]. This culture device allows for 
culture of MKs in a perivascular niche that closely mimics the in vivo biology. While there 
are a handful of other perivascular niche, fluidic models [146,147], the Balduini lab’s MK 
perivascular niche model is one of the only known reported culture system to recreate the 
BM perivascular niche in vitro. Platforms like these could be created to model other 
hematopoietic cell niches in the BM or to create more complete BM cultures.  
2.6 In vivo niche engineering 
 Another strategy for BM niche engineering has been the creation of ectopic BM in 
live animal models. By implanting scaffolds or hydrogels that are pre-seeded with stromal 
cells or that contain growth factors or cytokines for the recruitment of stroma, implants can 
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recruit hematopoietic cells from circulation and become vascularized to create an 
additional BM niche within the animal. In 2002, Krupnick et al showed that ectopic BM 
can be formed with as little as implanting BM cells and bone fragments suspended in a 
collagen type I gel [148]. Collagen scaffolds, heparinized to bind SDF1, implanted into 
mice are able to recruit a number of HPCs and stromal cells to create a microenvironment 
that can support differentiation of a limited number of hematopoietic cell types [149]. The 
use of collagen to create ectopic BM was further developed by the Ingber group in 2014; 
they showed that an implanted a collagen gel (loaded with demineralized bone powder, 
bone morphogenic protein 2 and 4) inside of a PDMS mold could form an ectopic marrow 
that could be removed an cultured ex vivo in a microfluidic device for up to 7 days [150]. 
Other scaffolds (including PA ICC [98] and PCL [104]) have also been used for the 
foundation of ectopic BM formation. This is a promising technique for the generation of 
an intricate BM niche that may be extremely useful for furthering the study of the BM 
niche. Although humanized ectopic BM implants have been produced [104] and further 
research may prove otherwise, this approach to BM engineering may be limited due to 
zoogenic complications and costs associated with animal intermediates.  
2.7 Summary 
 A viable engineered bone marrow model would be beneficial for advancing 
knowledge of the BM niche and could potentially be used for several clinical applications, 
although we are years away from any significant, direct clinical translation. The largest 
target for biomaterial-based BM niche clinical applications is the ex vivo expansion of 
HSCs for transplant. However, recently reported methods of ex vivo expansion of HSCs in 
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clinical trials use simple 2D MSC co-culture or soluble factors only [151]. Several 
innovations in the applications of materials chemistry toward HSC culture have furthered 
our understanding of HSC dependence on several variables in in vitro culture; although, 
our understanding of the BM niche is not complete, and we are still not able to fully 
replicate BM. Further studies of HSPC interaction and behavior when cultured on materials 
that mimic complex ECM microenvironments and stromal cell membrane presented factors 
are needed. Various tools are now available to researchers to answer these questions with 
much richer metrics than total culture expansion or formation of CFUs. The development 
of microcavity cultures will be useful for studying HSPC interaction with complex ECM 
environments [152] and could also be employed for studying stromal cell interactions while 
tracking single-cell fates [153], and thus supplying richer methods of evaluation. 
Microcavities can be a practical for screening single aspects of in vitro HSPC culture for 
optimizing several culture parameters. Microfluidics will also be an important instrument 
for studying specific BM niche conditions because controlled gradients of cytokines, ECM, 
or stromal co-culture cells can be established within these devices [115,154]. These 
methods need to be fully utilized for our understanding of the HSC niche to approach a 
complete model.  
 To create a culture system that replicates the entirety of the BM environment, 
including the various HSPC niches, a composite culture is likely to be required because of 
the discontinuous environment of BM. Over the last twenty years, most studies have 
focused on the mimicking the endosteal niche (partly due to the previous understanding of 
the location of the HSC niche). As our understanding of the niche changes, so must the in 
vitro culture systems that attempt to replicate in vivo behavior. The endotheliazed BM 
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niche for MKs [145] and the vascularized decellularized bone [103] are first steps in 
studying this niche and the role it plays with respect to maintaining and directing HSPCs. 
Studying the cross-talk between stromal and hematopoietic cells that exist within these 
distinct niches will also be important as we try to assemble a complete model of BM 
[114,155]. Not all applications require a complete replicate of the BM; applications 
requiring expansion or differentiation of specific cell types may only require a single niche 
mimic, however these culture systems would also benefit from a wider understanding of 
the interaction between HSPC niches and how hematopoiesis is regulated in vivo. For these 
models to be developed, materials are required that can be tuned to replicate specific 
chemical, biological, and physical attributes of the BM niche.  
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CHAPTER 3. AIM 1A: DESIGN AND FABRICATION 
3.1 Introduction 
 Microfluidic systems have been developed over the last 20 years for a wide variety 
of laboratory applications [156-160]. While standard, 2D cell culture techniques are simple 
and reliable, they do not allow for the complex, 3D arrangement of cells and ECM that can 
be achieved using microfluidic platforms. Organ-on-a-chip platforms that replicate basic 
3D physiologic structures have been developed for lungs [161], gut [162], kidney [163], 
eye [164], and many other organ or tissue systems. These organ platforms have even been 
integrated together to create “human-on-a-chip” systems, composed of up to 10 
interconnected organ models [165]. The design of several organ-on-chips rely on 
microfabrication of environments that create controlled barriers between, or arrangement 
of specific cell types that replicate the basic structures of native tissues. 
 PDMS has been an instrumental material for the development of microfluidic 
platforms in the laboratory setting. As a material for platform development, PDMS when 
used in soft lithography has many advantages, (1) it allows for rapid prototyping of 
microfluidic designs, (2) it is relatively inexpensive, (3) it is gas permeable allowing for 
prolonged cell culture, and (4) it is optically transparent which permits in-process imaging 
of the cells. However, there are some disadvantages to using PDMS as a cell culture 
material. PDMS can absorb small hydrophobic molecules, which can be problematic in 
drug screening applications [166]. Additionally, untreated PDMS is hydrophobic and does 
not readily support the attachment of adherent cells to its surface unless it is treated to 
promote sustained adsorption of adhesion proteins to the surface. Despite these drawbacks, 
 42 
they are outweighed by the advantageous of using PDMS and it is widely used for the early 
development of organ-on-a-chip platforms. 
 The first and most widely used design of organ-on-chips consists of two channels, 
one on top of the other, separated by a membrane [161]. Recently, there has been work 
focused on creating multiple, interconnected microenvironments within a single 
microfluidic device without the use of a porous membrane to separate the discrete 
microenvironments. Microfluidic devices with PDMS posts separating adjacent channels 
allow for the controlled loading and placement of distinct hydrogels that can be seeded 
with different cell types to create complex arrangements of cells and environments [167]. 
Variations of this design, with a central hydrogel channel and flanking media channels, 
have been used extensively for angiogenesis and vasculogenesis studies where endothelial 
cells are cultured within a hydrogel in a central channel and are stimulated by cytokines or 
stromal cells (typically fibroblasts) situated in flanking hydrogel channels [147,168-171]. 
Compared with the more widely used approach of isolating endothelial cells in an entirely 
separate channel with a permeable barrier connecting the environments, using PDMS posts 
to create a 3D, hydrogel environment creates microvasculature that better mimics the 
structures found in native tissues. 
 Using a previously published approach for the basic design of the microfluidic 
device, here we present the design and fabrication methods of an hBM-on-a-chip device 
that supports the culture of both the endosteal niche and the perivascular niche. In addition, 
we implemented multiple techniques that progressed the device fabrication from a 
prototype, small-scale process to a reproducible, medium-scale process that enables the 
integration of hBM-on-a-chip into a standard well-plate format. 
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Figure 8. Early iterations of hBM-on-a-chip design. (A) Horizontal orientation of the 
endosteal and vascularized marrow niches in a 4-channel device resulted in inconsistencies 
in hydrogel interface formation and in incomplete formation of the endosteal niche. (B) A 
3-channel device with vertically arranged endosteal and vascularized marrow niches 




3.2.1 Iterations of hBM-on-a-chip design 
 Our first design of hBM-on-a-chip consisted of horizontally adjacent channels that 
were to contain distinct bone and vascularized marrow microenvironments (Figure 8A). 
MSCs were first differentiated into osteoblasts for 10 days on TCPS and then loaded into 
the device in a collagen type I hydrogel. Subsequently, human umbilical vein endothelial 
cells (HUVECs) and MSCs were loaded within a fibrin hydrogel in the adjacent channel 
to form the “vascularized marrow” of the device. While this approach offered many 
advantages, including microenvironments separated in the x-y plane that could allow for 
clear delineation of the marrow microenvironments, there were several technical 
challenges that ultimately led to the redesign of the device. Among the technical challenges 
in implanting this design were: (1) delamination and ultimately collapse of the collagen 
type I hydrogel culture due to the contractile pull of the OBs; (2) difficulty achieving a 
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reliable interface between the two hydrogels (Figure 9A); and (3) incomplete formation of 
the endosteal niche because the hydrogels are loaded at the same time and there is no 




Figure 9. Limitations of horizontal arrangement of hBM-on-a-chip. (A) The interface 
between collagen (lower) and fibrin (upper) hydrogels was inconsistent and would 
frequently form air bubbles. (B) Alizarin red staining in endosteal niche (left) after 5 days 
of culture was minimal compared to marrow niche (right). Scale bar: 100 µm. 
 
 
 To overcome these limitations, a second generation of the hBM-on-a-chip was 
designed (Figure 8B). In the redesigned device, OBs were first seeded on the surface of the 
central channel and then HUVECs and MSCs were subsequently seeded on top of the 
“endosteal surface.” This change in device designed addressed the technical challenges 
discussed above by: (1 & 2) OBs were no longer culture within a collagen type I hydrogel, 
but rather they were cultured on the PDMS surface, this eliminated hydrogel contraction 
and interface problems; and (3) eliminating the need for seeding the HUVECs and MSCs 
at the same time as the OBs allowed for prolonged culture of OBs and development of an 
endosteal niche. This redesign was successful, however a small alteration was made by 
adding outer hydrogel channels for the loading of stromal cells that supported 
vasculogenesis [170].  
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Figure 10. Approach for hBM-on-a-chip. (A) A 5-channel PDMS microfluidic device 
was fabricated using standard soft lithography techniques. MSCs are first differentiated for 
21 days in the central channel of the device to form an endosteal layer, then HUVECs, 
MSCs, and HSPCs are loaded on top of the endosteal layer and vasculogenesis occurs over 
5 days to form the hBM-on-a-chip. (B) The hBM-on-a-chip can recapitulate both the 
central perivascular BM niche (without OBs) and the vascularized endosteal BM niche 
(with OBs) that are found in the cavities of long bones.  
 
 
3.2.2 Design of hBM-on-a-chip with simple, in-vitro design 
 A five-channel device was designed and fabricated with a height of 120-150 µm 
and consists of one central gel channel, two media channels, and two outer gel channels 
(Figure 10 and Figure 11). The process for culturing cells and creating the BM 
microenvironment involved first seeding MSCs in the central channel where the MSCs are 
differentiated over 21 days to form the endosteal niche. Second, HUVECs, MSCs and 
HSPCs were seeded on top of the endosteal layer and cultured for 5 days to allow for 
vascular formation prior to experimentation. The device was designed similarly to recently 
published methods [170,171], but with modifications that (1) promoted maintenance of the 
air-liquid interface between the central channel and adjacent media channels, and (2) 
allowed for loading of cells and hydrogel precursors into a previously wetted channel. 
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 Essential to this approach is the ability to wet the central channel during the 
differentiation of MSCs while keeping the adjacent media channels dry throughout the 
process so that a second set of cells can be loaded within the central channel. To achieve 
this, the pores between the gel channels were narrowed (compared to similar, previously 
published devices) to 50 µm in width and the number of communication pores was limited 
to decrease the occurrence of media leaking from the central channel during osteogenesis 
(Figure 11C-E). Additionally, many previously published devices of similar design use a 
glass coverslip as a bottom surface of the device. However, glass is more hydrophilic than 
PDMS, and using glass as the bottom surface would not permit extended maintenance of 
the air-liquid interface between channels during extended culture. To overcome this, a 
PDMS surface (either a PDMS coated coverslip or a thin PDMS film) was used as the 
bottom surface of hBM-on-a-chip. With these modifications, the difference between 
advancing pressure and burst pressure is substantial, it was calculated to be 282 mmH2O 
which allows for simple manual loading of fluid into the device without leakage into the 
adjacent media channels. However, the extended culture of the devices in a humid 
environment results in wetting of interior, dry surfaces of PDMS that leads to “failure” of 
the devices by leakage of the culture media into the adjacent media channels, which 
prevents subsequent isolated loading of cells in the central channel. This was mitigated by 
thorough cleaning of the devices with 70% EtOH and t drying overnight at 65 ºC and 
produced devices that “survived” the 21-day culture at a rate >90% (Figure 13). 
 To culture cells for a prolonged period and then load cells into the previously wetted 
channel, the central channel required both a media reservoir, to contain enough media 
during culture, and an accessible loading port (Figure 11B). This feature differentiates this 
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device from previously published methods, which do not require both prolonged culture 
prior to loading of a hydrogel and therefore can use only a single 1 mm loading port for the 
hydrogel channels. To include this design criteria into the PDMS device, it was necessary 
to adapt a multi-step approach to fabrication.  
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Figure 11. Design details and fabrication process of v1.0 and v1.1 hBM-on-a-chip. (A) 
The 5-channel PDMS microfluidic device was accessible through 1-mm gel loading ports 
(for central and outer channels) and media loading ports. (B) These 1-mm loading ports 
were accessible through 4-mm media reservoirs that permitted sustained culture in media 
using both the central channel (during osteogenesis) and the media channels (during 
vasculogenesis). (C) Each channel has a width of 1000 µm and the channels are connected 
via 11 communication pores that are formed by 10 posts. (D) The communication pores 
are 50 µm in width and are designed to enable consistent formation of air-liquid-interface. 
(E) Example of air-liquid interface formed at a communication pore. (F) For v1.0, PDMS 
features were fabricated using standard soft lithography techniques. (1) A silicon wafer 
was spun coat with SU-8 photoresist, (2) exposed to UV light through a patterned 
photomask and (3) then the uncrosslinked SU-8 was removed leaving the patterned, SU-8 
master mold. Then, (4) PDMS was cast on the SU-8 master mold and loading ports were 
created in the PDMS device layer. (G) The PDMS device layer was bonded to a PDMS 
media reservoir layer and to a PDMS coated coverslip to create a finished device. (H) For 
v1.1, the initial steps of fabrication (1-4) were unchanged from version 1.0. (5) To form 
the media reservoirs, a 3D printed mold was placed on top of the PDMS device layer and 
additional PDMS was cast to form the media reservoirs, after which (6) loading ports were 
made. (I) The PDMS device/media reservoir layer was plasma bonded to a thin PDMS film 
and cut into individual devices.  
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Table 1. Version 1.0 device fabrication. 
Step Description Time (per device) Efficiency Variability 
Cast PDMS on SU-8 
master mold 
• Mix PDMS 10:1 
• Pour and degas 
• Cure at 65 ºC 
1 100% Low 
Cast PDMS reservoir 
layer  
• Mix PDMS 10:1 
• Pour and degas 
• Cure at 65 ºC 
• 20 devices per batch 
0.5 100% Low 
Cut + punch ports in 
device layer 
• Punch ports 
• Cut devices 
0.5 100% Low 
Cut + punch holes in 
reservoir layer 
• Cut devices 
• Punch holes 
0.5 90% Low 
Plasma bond device 
layer to reservoir layer 
• Plasma activate 
• Align and bond 
• 3 devices/batch 
1 90% Low 
PDMS coat coverslips • Coat coverslips 
• Cure at 65 ºC 
0.5 80% High 
Plasma bond device to 
reservoir to coverslip 
• Plasma activate 
• Align and bond 
• 3 devices/batch 
1 90% High 
 TOTAL 5 min 58% High 
 
Table 2. Version 1.1 device fabrication. 
Step Description Time (per device) Efficiency Variability 
Cast PDMS on SU-8 
master mold 
• Mix PDMS 10:1 
• Pour and degas 
• Cure at 65 ºC 
1 100% Low 
Cast PDMS reservoir 
layer w/ 3D printed 
mold 
• Mix PDMS 10:1 
• Place 3D-printed 
mold 
• Pour PDMS 
• Cure at 65 ºC 
1 90% Medium 
Punch holes in device 
layer 
• Remove PDMS from 
3-D printed mold 
• Punch holes 
• Cut devices 
0.5 100% Low 
Cast PDMS film • Coat petri dish 
• Cure at 65 ºC 
0.5 100% Low 
Plasma bond PDMS 
device to PDMS film 
• Plasma activate 
• Align and bond 
• 12 devices/batch 
0.25 95% Low 
Cut individual devices 
 
0.25 100% Low 




Figure 12. v2.0 device fabrication. (A) The initial steps of fabrication (1-4) were 
unchanged from v1.0. To assemble a 2x4 array of devices, a polyurethane master mold was 
cast from two 2x2 device arrays. (B) The device layer of PDMS was first bonded to a thin 
PDMS film, then using a chemical gluing technique, the device layer was bonded to a 
bottomless 96-well plate. (C) The resulting device created a 2x4 array of devices that 
utilizes the wells of the well plate as media reservoirs, loading ports, and imaging windows. 




Table 3. Version 2.0 device fabrication. 
Step Description Time (per device) Efficiency Variability 
Cast PDMS on SU-8 
master mold 
• Mix PDMS 10:1 
• Pour and degas 
• Cure at 65 ºC 
1 100% Low 
Punch holes in PDMS 
device layer 
• Punch holes 
• Cut devices 
0.5 100% Low 
Cast PDMS film • Coat petri dish 
• Cure at 65 °C 
0.5 100% Low 
Plasma bond PDMS 
device to film 
• Plasma activate 
• Align and bond 
• 8 devices/batch 
0.38 100% Low 
Plasma bond PDMS 
device to 96-well plate 
• Silane treat plate 
• Plasma activate 
• Align and bond 
8 devices/batch 
0.38 100% Low 
Plasma bond cover glass 
to device 
• Plasma activate 
• Align and bond 
• 8 devices/batch 
0.38 100% Low 




3.2.3 High-throughput fabrication of hBM-on-a-Chip 
During our initial studies, we approached this challenge by fabrication a 3-layer 
PDMS device (Figure 11F, G) consisting of (1) a PDMS coated glass coverslip, (2) a 
middle-feature layer, and (3) a reservoir layer. This fabrication method was appropriate 
and useful for initial studies because it allowed for fabrication of individual devices while 
failure rates were high, and its modular composition permitted parallel iteration of the 
component parts. However, as the design because finalized, this fabrication method proved 
to be inefficient, time intensive, and generated variable final products (Table 1). The 
individual coating of coverslips with PDMS produced non-uniform surfaces and the 
bonding of these coverslips to the device created devices that were not consistently oriented 
with respect to the coverslip, which impaired downstream imaging and analysis because 
each device was uniquely oriented. 
To improve efficiency of fabrication, we developed a simplified method that 
combined the feature layer and the reservoir layer through a two-step PDMS casting 
protocol where a 3D printed mold was used to create media reservoirs (Figure 11H, I). This 
fabrication protocol substantially decreased device fabrication time and increased material 
efficiency (Table 2). Additionally, the PDMS coated glass coverslip was replaced with a 
thin PDMS film that creates a more uniform surface and decreased device variability. 
To further improve on the design and standardization of hBM-on-a-chip, a 
microfluidic platform was developed to integrate the platform into a standard, well-plate 
format. Using previously published methods [172-174], the PDMS “device” layer was 
bonded directly to a commercially available, bottomless 96-well plate (Figure 12A, B). The 
resulting array of 8 devices uses the wells of the plate as media reservoirs and as a window 
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for imaging the central channel of the device (Figure 12C). This process creates an array 
of devices that are consistently oriented within known well locations, making the platform 
easily transferable to automated imaging, or potentially, media handling instrumentation. 
An unexpected benefit of moving to this fabrication method was the increased “survival” 
of devices during the 21-day differentiation of MSCs. Most likely because the PDMS 
portion of the construct is fixed to a rigid polystyrene frame, there are no longer small 
deformations due to handling of the devices during loading and culture, which results in a 




Figure 13. “Survival” of devices during 21-day differentiation. “Survival” of viable 
devices using (A) v1.1 and (B) v2.0 hBM-on-a-chip device. Devices “fail” when media 
leaks from the central channel into adjacent media channels, rendering it impossible to 
isolate the central channel when loading cells on top of the endosteal layer. 
 
 
3.2.4 Enabling cell attachment to PDMS surface 
 A challenge that had to be overcome for this approach was the sustained adhesion 
of MSCs to the PDMS surface during differentiation to OBs. Untreated PDMS is 
hydrophobic and does not support the attachment of adherent cells [175]. To allow for cell 
attachment, the surface must be treated or coated with an ECM protein. We investigated 
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the coating of the PDMS surface with collagen type I and FN (Figure 14) and found that 
fibronectin allowed for moderate initial adhesion, while collagen type I marginally 
improved adhesion over PDMS alone. We then attempted a previously published approach 
for improving PDMS coating where the PDMS is first coated with polydopamine (0.01%) 
which improves the adsorption of collagen type I to the PDMS surface. Using this 
technique, we observed substantially improved adhesion of MSCs to the PDMS surface 




Figure 14. ECM coating to promote MSC adhesion to PDMS. Phase contrast images of 
MSCs 24 hours after seeding in PDMS hBM-on-a-chip devices that were uncoated or 
coated with collagen 1 (100 µg/mL), fibronectin (100 µg/mL), or PDA (0.01%) and 




3.3.1 Photomask design 
Photomasks (CAD/Art Services) were designed using AutoCAD software 
(Autodesk). Photomasks were specified as right-read, darkfield, emulsion down. A detailed 
description of photomask design criteria can be found in Appendix B. 
3.3.2 Soft lithography 
 An SU-8 master mold was fabricated using previously described soft lithography 
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techniques [176]. Briefly, SU-8 2150 (MicroChem) was spun to a thickness of ~120 µm 
on a silicon wafer (University Wafers) using a G3P8 Spin Coater (SCS). SU-8 was exposed 
with UV light through the photomask using an MJB4 mask aligner (Suss Microtec). 
Uncrosslinked SU-8 was removed with SU-8 developer (MicroChem) and silicon wafers 
were treated by vapor phase deposition of trichloro(1H,1H,2H,2H-perfluorooctyl silane 
(Sigma-Aldrich) to increase surface hydrophobicity. A detailed protocol can be found in 
Appendix B. 
3.3.3 PDMS device fabrication 
3.3.3.1 Version 1.0 device fabrication 
 PDMS (Dow Corning) was mixed 10:1 (elastomer base: curing agent) and cast on 
SU-8 master mold. PDMS was cured at 65 °C. The PDMS layer containing the features 
was then removed from the master mold and loading ports were made using a 1 mm biopsy 
punch (Integra Miltex). To form the media reservoir layer, PDMS was mixed 10:1 and cast 
in a 100 mm petri dish to a thickness of 5-6 mm. PDMS was cured at 65 °C. The thick disc 
of PDMS was then cut into single-device sized squares and media reservoirs were made 
using a 4 mm biopsy punch. The top surface of the device layer was then bonded to the 
media reservoir layer using a plasma cleaner (Harrick Plasma). To form the PDMS coated 
coverslips, PDMS was mixed 10:1 and 50 µL were applied to a clean glass coverslip, the 
coverslip was then sheared against a glass slide to evenly coat the surface and the PDMS 
was cured at 65 °C. The PDMS coated coverslip was then bonded to the bottom surface of 
the device layer using a plasma cleaner (Figure 11). Prior to use, devices were washed with 
70% EtOH.  
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3.3.3.2 Version 1.1 device fabrication 
PDMS was mixed 10:1 and cast on SU-8 master mold. PDMS was cured at 65 ºC. 
The PDMS layer containing the features was then removed from the master mold, a 3D 
printed reservoir mold was aligned on top and additional PMDS (10:1) was poured on top 
of the device to form media reservoirs. After curing at 65 ºC, loading ports were made 
using 1 mm biopsy punch. A thin film of PDMS was made by mixing PDMS 5:1, casting 
a thin layer (~300 µm) in a 150 mm petri dish and curing at 65 °C. Devices were bonded 
to the thin film of PDMS using a plasma cleaner, and individual devices were cut for use 
in cell culture (Figure 11). Prior to use, devices were washed with 70% EtOH. 
3.3.3.3 Version 2.0 device fabrication 
hBM-on-a-chip was integrated into a standard well-plate format using previously 
published methods (Figure 12) [172-174]. Because a standard 100 mm silicon wafer does 
not have enough area to pattern the entire 4x2 hBM-on-a-chip array (Figure 45), a 
polyurethane master mold was first fabricated from PDMS cast on a SU-8 master. PDMS 
was mixed 10:1 (elastomer base: curing agent) and cast on the SU-8 master mold () to 
create two copies of the 2x2 array. The two pieces were aligned, feature-side down, and 
made into a single block by casting in additional PDMS. A polyurethane master mold was 
then cast on the single PDMS piece containing the 4x2 array using a 2-part polyurethane 
liquid plastic (Smooth Cast 310, Smooth-On Inc.) [173]. To prevent adhesion of PDMS 
subsequently cast, the polyurethane master mold was treated by vapor phase deposition of 
trichloro(1H,1H,2H,2H-perfluorooctyl) silane (Sigma-Aldrich). 
PDMS was mixed 10:1, cast on the polyurethane master mold, and cured at 65 °C. 
The PDMS layer containing the features was then removed from the master mold and 
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loading ports were made using a 1 mm biopsy punch. A thin film of PDMS was made by 
mixing PDMS 5:1, casting a thin layer (~600 µm) in a 150 mm petri dish and curing at 65 
°C. The feature layer of PDMS was then bonded to the PDMS film using a plasma cleaner. 
The bonded PDMS devices were then attached to a bottomless 96-well plate (Greiner Bio-
One) using a chemical gluing method [174]. Briefly, the 96-well plate was immersed in 
2% (v/v) 3-mercaptopropyl trimethoxysilane (Sigma-Aldrich) in methanol for 1 minute, 
rinsed with deionized H2O, and dried. The bonded PDMS devices were then plasma bonded 
to the 96-well plate using a plasma cleaner. To provide support to the bottom PDMS 
surface, glass coverslips (Fisher Scientific) were adhered to the PDMS film by plasma 
bonding. Prior to use, devices were washed with 70% EtOH and DI H2O. 
3.3.4 Burst pressure calculations 
Burst pressure was calculated using an approached described by Wang et al. 2016, 
which is briefly described below [177]. The pressure difference at the air-liquid interface 
for advancing liquid within the gel channel can be represented by the Young-Laplace 
equation (Equation 1): 
 







Where Pliquid advance is the liquid pressure inside the gel channel, γ is surface tension (γ = 
0.072 N m-1), θA is the critical contact angle where liquid will burst or advance (θA = 140º), 
w is the width of the channel, and h is the height of the channel. The advancing pressure 
for liquid within gel channel (wchannel = 1000 µm, h = 150 µm) was found to be 845 Pa or 
86 mmH2O.  











Where θA* is the contact angle of the liquid with the inner facing side wall of the channel 
dividers (however, θA* is limited to 180º, the maximum contact angle for a liquid meniscus). 
The burst pressure at the communication pores (wpore = 50 µm, h = 150 µm) is 3615 Pa or 
369 mmH2O.  
 The difference between Pliquid advance and Pliquid burst is 2770 Pa or 282 mmH2O. 
3.3.5 Surface coating of PDMS 
To promote cell adhesion, the central gel channel was coated with 0.01% dopamine 
HCl (Sigma-Aldrich) in TE Buffer [pH 8.5] for 1 hour at room temperature, washed with 
PBS, coated with 100 µg/mL rat tail collagen I (Corning) in PBS for 1 hour at room 
temperature, washed with PBS, and then dried overnight at 65 ºC [178]. Devices were 
sterilized by UV exposure for at least 30 minutes prior to culture of cells. 
3.4 Discussion 
The approach and design of the hBM-on-a-chip went through several iterations in 
order to produce a simple and more reproducible device. The design that was initially 
proposed, a horizontal juxtaposition of the endosteal and perivascular microenvironments 
had several theoretical advantages: the two microenvironments were separated in the x-y 
plane, which would have allowed for simple niche classification during imaging; and the 
two niche hydrogels were loaded simultaneously, which would have permitted shorter 
culture times for the devices. However, these two theoretical advantages proved to be 
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logistical weaknesses of the design. Given the previous published work with horizontal 
arrangement of the hydrogels [167], this approach is feasible, but we found the method to 
be inconsistent. While changing the design to a single BM channel, where the endosteal 
niche is formed and then the vasculature seeded on top of it, increased the duration of 
culture, it was a simpler approach that resulted in more consistent hBM-on-a-chip culture.  
The fabrication methods for hBM-on-a-chip were iterated to create an improved 
hBM-on-a-chip. Improving upon the fabrication process for PDMS based organ-on-chips 
not only decreases the fabrication time and increases the inter-device consistency, but we 
have created a more robust process that is standardized to make hBM-on-a-chip more easily 
reproduced by other researchers.  
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CHAPTER 4. AIM 1B: CULTURE AND CHARACTERIZATION 
4.1 Introduction 
 As we have described, BM is complex, heterogeneous, with distinct 
microenvironments. We can simplify our concept of BM to three basic microenvironments: 
the endosteal niche, the central marrow, and the perivascular niche. Osteoblasts reside on 
the endosteal surface of bone creating a microenvironment that is composed of mineralized 
matrix, and contains hematopoietic cytokines like CXCL12, SCF, JAG1, and OPN. The 
vasculature of the BM permeates through the organ and varies in size. Large BM sinusoids 
(>35 µm) are located in the center of BM, and smaller vessels (15-35 µm) and 
microvasculature (5-15 µm) branch off from the sinusoids into surrounding BM tissue, 
towards and into the bone itself [25]. 
 There are many previously published in vitro methods that recreate the individual 
components of the BM microenvironment. The differentiation of MSCs into OBs, 
osteogenesis, is a common in vitro technique for the generation of bone tissue [179]. 
Osteogenesis is dependent on small molecules (e.g. dexamethasone, β-glycerophosphate, 
ascorbic acid), biologic (e.g. bone morphogenic proteins), ECM (e.g. fibronectin, 
collagen), and other physical or chemical variables (e.g. surface stiffness, hypoxia) 
[51,180,181]. There are several examples of these methods being applied in microfluidic 
cultures [178,182]. 
 As discussed in CHAPTER 3, there are also a number of published methods for 
creating self-assembled vascular networks in microfluidic devices [183] and this was a 
primary factor in the design of the hBM-on-a-chip. Vasculogenesis is dependent on 
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mechanical (shear stress, interstitial flow), biochemical (e.g. VEGF, Ang-1), and biological 
factors (EC tissue source, co-culture with mural cells) [184] that can influence the rate and 
quality of networks formed in vitro.  
 Using hBM-on-a-chip devices that were developed and fabricated in CHAPTER 3, 
in this chapter we sought to develop methods for culture and characterization of the 
resulting BM microenvironments. First, we developed methods for the formation of the 
endosteal niche. Next, we optimized conditions for vasculogenesis and the creation of the 
perivascular niche. Finally, we investigated the inclusion of HSPCs in hBM-on-a-chip with 
and without stromal cells present. 
4.2 Results 
4.2.1 Osteogenesis in hBM-on-a-chip 
 The first process in the hBM-on-a-chip culture is the formation of the endosteal 
niche. Our original approach was to pre-differentiate MSCs into OBs over a 14-day period, 
then to load the OBs into the central channel of the device and culture for 10 days to form 
the endosteal niche within the microfluidic device. The strategy was originally chosen 
because it limited the culture time where an air-liquid interface was required to be 
maintained between the central channel and adjacent media channels. This was an 
especially attractive approach during early device development when we had not optimized 
the design of the device to accommodate extended, isolated culture in the central channel. 
We observed moderate deposition of mineralized matrix through Alizarin red (Figure 15A) 
and von Kossa (Figure 15B) staining; however, 10 days of culture was not enough to get 
consistent staining of the PDMS surface. There were two options for improving the results 
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using this approach: (1) to increase the differentiation time prior to device loading or (2) to 
increase the culture time within the device. Increasing the differentiation time prior to 
loading was practically difficult, as MSCs underwent osteogenesis they deposited a 
significant amount of ECM and become increasingly more difficult to harvest from a TCPS 
surface. Increasing the culture time within the device became more practical as the design 
of the device was optimized for this purpose, however, to simplify the cell sources for 
ongoing experiments we chose to complete a full 21-day differentiation of MSCs within 




Figure 15. 10-day osteogenesis of pre-differentiated OBs to form the endosteal niche. 
(A) Alizarin red and (B) von Kossa staining of MSCs first pre-differentiated for 14 days 
on TCPS then differentiated an additional 10 days in hBM-on-a-chip.  
 
 
 MSCs were seeded at a high density (5x105 cells/mL) within the central channel of 
the device and differentiated with osteogenic media over a period of 21 days. 
Mineralization of matrix was observed by Alizarin red (Figure 16A,B) and von Kossa 
(Figure 16C,D) staining. Mineralization increased over the 21-day differentiation. At 21 
days, 71 ± 18% of the area of the device stained positive for Alizarin red and the normalized 
mean intensity of the stained device was 0.64 ± 0.07. Similarly, at 21 days 91 ± 3% of the 
area of the device stained positive for von Kossa and the normalized mean intensity was 
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0.60 ± 0.06. In addition to mineralized matrix, the expression of specific cytokines and 
ECM components is of interest when creating a surrogate endosteal niche. After 21 days 
differentiation, the differentiated MSCs expressed cytokines (SCF, CXCL12, and JAG1) 





Figure 16. 21-day osteogenesis of MSCs to form the endosteal niche. MSCs were 
differentiated for 21 days within the central channel of the hBM-on-a-chip after which 
mineralization was measured. Representative images of (A) alizarin red and (C) von Kossa 
staining. Scale bars: 500 µm. Quantification of (B) alizarin red and (D) von Kossa staining 
by (i) percent area and (ii) mean intensity. Data are plotted as mean ± SD (n = 3 devices). 
Immunofluorescence staining of endosteal cytokines (E) CXCL12, (F) SCF, and (G) 
jagged-1. Immunofluorescence staining of endosteal ECM (H) fibronectin, and (I) 
osteopontin, was observed using immunofluorescence staining. Scale bars: 100 µm.  
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Figure 17. Effect of stromal cells on vasculogenesis in fibrin hydrogel without cytokine 
stimulation. (A) Immunofluorescence staining of CD31 (red) and F-actin (yellow) after 5 
days vasculogenesis in hBM-on-a-chip with or without MSCs and OBs using a fibrin (5 
mg/mL) hydrogel without any additional cytokine stimulation. Quantification of the (B) 
percent area and (C) total length of vascular networks. Data are plotted as mean ± SEM (n 
= 4-6 devices). Data were analyzed using a one-way ANOVA with Tukey’s post hoc test. 
No significance found at p < 0.05. 
 
 
4.2.2 Vasculogenesis in hBM-on-a-chip 
 Once the endosteal niche was formed, HUVECs and MSCs were suspended in a 
fibrin (5 mg/mL) hydrogel and loaded on top of the endosteal surface. Using a 5-channel 
device, as described in CHAPTER 3, MSCs were simultaneously loaded into the outermost 
channels in order to produce pro-vasculogenic cytokines and induce vascular formation. 
To determine the effect of stromal cells on vasculogenesis, we made devices with and 
without MSCs and OBs and measured the resulting vascular formation (Figure 17). F-actin 
staining of all cells (endothelial cells were differentiated by CD31 expression) showed 
perivascular stromal cells in MSC containing conditions and an endosteal layer in OB 
containing groups (Figure 17A). Qualitatively, the resulting vascular networks appeared 
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different. EC-only vasculature appeared larger and less homogeneous, while MSCs and 
OBs appeared to produce more consistent vasculature and decrease the vessel diameter. 
However, analysis of the vascular networks did not find any significant differences 




Figure 18. Optimization of hydrogel composition and cytokine supplementation for 
vasculogenesis. (A) Perfusion of vascular networks with 70 kDa dextran-FITC in hBM-
on-a-chip (EC+MSC) using fibrin only (5 mg/mL) or fibrin-collagen co-gel (3 mg/mL, 2 
mg/mL), with and without VEGF (50 ng/mL) and Ang-1 (100 ng/mL) supplementation. 
(B) Perfusion of vascular networks with 70 kDa dextran FITC in hBM-on-a-chip (without 
OB) with VEGF (50 ng/mL) and Ang-1 (100 ng/mL) supplementation, using fibrin only 
(5 mg/mL) or fibrin-collagen co-gels at 4:1 or 3:2 ratios Scale bar: 1000 µm.  
 
 
 While MSCs in the flanking channels were successfully promoting vasculogenesis, 
we observed that these vascular networks were not consistently forming open lumens at 
the channel pores and as a result were not consistently perfusable. To address this, we 
investigated how hydrogel composition and added cytokine supplementation might 
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improve the perfusability of the vascular networks (Figure 18). Using devices with MSCs 
and HUVECs only, we tested both fibrin (5 mg/mL) and fibrin-collagen I co-gels (3 mg/mL 
and 2 mg/mL) with and without added VEGF or Ang-1 (Figure 18A). Devices with the 
fibrin-collagen I co-gel supplemented with VEGF (50 ng/mL) and Ang-1 (100 ng/mL) 
produced vascular networks that were perfusable by 70 kDa dextran. To further optimize 
the hydrogel composition, we next tested three different hydrogel compositions with added 
cytokine supplementation: fibrin (5 mg/mL) only, fibrin-collagen I (4 mg/mL fibrin, 1 
mg/mL collagen) and fibrin-collagen (3 mg/mL fibrin, 2 mg/mL collagen) (Figure 18B). 
The fibrin-collagen co-gel (4 mg/mL fibrin, 1 mg/mL collagen) produced more consistent, 
perfusable vascular networks than the co-gel with larger proportion of collagen I.  
 Using the fibrin-collagen I co-gel with supplemental cytokines (VEGF and Ang-1), 
hBM-on-a-chip microfluidic devices were created with and without MSCs and the 
differentiated endosteal layer (OBs) to measure the effect of stromal cells on 
vasculogenesis and cytokine secretion (Figure 19A). We observed no significant difference 
in the vasculature area containing MSCs (41.4 ± 4.4%), OBs (44.1 ± 2.9%), or both cell 
types (44.3 ± 3.1%) when compared between groups or to devices containing ECs only 
(43.39 ± 3.3%) (Figure 19B). Similarly, no significant difference in the total length of the 
vasculature networks was observed between devices containing MSCs (83.0 ± 13.0 mm), 
OBs (92.9 ± 12.2 mm), both MSCs and OBs (92.1 ± 10.8 mm), or neither (83.3 ± 6.2 mm) 
(Figure 19C). Although there was no significant difference, it is worth noting that the 
devices containing OBs exhibited vasculature that covered marginally less area and had a 
slightly increased total length of the network, which indicated a smaller average diameter 
of the newly formed vasculature compared to devices without OBs.  
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Figure 19. Effect of stromal cells on vasculogenesis in fibrin-collagen I co-gel with 
VEGF and Ang-1 supplementation. hBM-on-a-chip with or without MSCs and OBs 
created using a fibrin (4 mg/mL) and collagen I (1 mg/mL) co-gel with VEGF (50 ng/mL, 
days 1-5) and Ang-1 (100 ng/mL, days 3-5) supplementation. (A) Immunofluorescence 
staining of CD31 (red) and F-actin (orange). Scale bars: 100 µm. Quantification of the (B) 
percent area and (C) total length of vascular networks. Data are plotted as mean ± SD (n = 
4-6 devices). Data were analyzed using a one-way ANOVA with Tukey’s post hoc test. No 
significance found at p < 0.05. (D) Hematopoietic cytokine secretion measured in device 
supernatant collected on day 5. Data are plotted as mean ± SEM (n = 4 devices). Data were 
analyzed using Kruskal-Wallis w/ Dunn’s post hoc test. Significance between groups (p < 
0.05) is indicated in the figure.  
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4.2.3 Expression of cytokines and ECM in hBM-on-a-chip 
 We observed differences in cytokine expression as a function of stromal cell 
inclusion using multiplex cytokine detection to analyze the supernatant collected from the 
devices on day 5 of vasculogenesis (Figure 19D). OB containing devices, in general, 
secreted higher amounts of cytokines. IL-6, a cytokine involved in B cell differentiation, 
was highly expressed in EC+OB (624 ± 212 pg/mL) and EC+MSC+OB (386 ± 49 pg/mL) 
samples, less was expressed in EC (162 ± 49 pg/mL) and EC+MSC (132 ± 34 pg/mL). IL-
11, which is responsible for signaling during megakaryocyte maturation, was measured in 
substantial concentrations in EC+OB (308 ± 73 pg/mL) and EC+MSC+OB (254 ± 64 
pg/mL) devices, while trace concentrations were detected in EC (4.1 ± 1.8 pg/mL) devices 
and not at all in EC+MSC samples. Similarly, M-CSF, which induces macrophage 
differentiation of HSCs, was elevated in EC+OB (58.3 ± 5.3 pg/mL) and EC+MSC+OB 
(68.6 ± 2.1 pg/mL) devices, while little was detected in EC (15.2 ± 7.6 pg/mL) and 
EC+MSC (10.3 ± 3.5 pg/mL) devices.  
 Relatively small concentrations of IL-7 (promoter of lymphopoiesis), IL-34 
(monocytes and macrophages), GM-CSF (granulocytes and macrophages), FLT-3L 
(dendritic cells), and SCF (HSC maintenance) were measured and there was no significant 
difference across groups. For both CXCL12 (hematopoietic chemoattractant) and IL-3 
(myeloid progenitors), no measurable analytes were detected. A limitation of microfluidic 
cell culture is the small volume of media that is accessible to the cells and the small number 
of cells in each culture, which can result in low (and in this case below detection) 
concentrations of analytes. To circumvent this issue and obtain more concentrated samples, 
we were also able to recover the central hydrogel and assay the cell containing portion of 
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the device directly by cutting through the bottom PDMS film and retrieving the central 
hydrogel. However, this approach resulted in no increase in the recovery of soluble 




Figure 20. Comparison of cytokine recovery from supernatant and hydrogel. hBM-
on-a-chip with or without MSCs and OBs created using a fibrin (4 mg/mL) and collagen I 
(1 mg/mL) co-gel with VEGF (50 ng/mL, days 1-5) and Ang-1 (100 ng/mL, days 3-5) 
supplementation. Hematopoietic cytokine secretion measured in device supernatant and in 
central hydrogel after 5 days of vasculogenesis Data are plotted as mean ± SEM (n = 4 
devices). Data were analyzed using Kruskal-Wallis w/ Dunn’s post hoc test. Significance 
between groups (p < 0.05) is indicated in the figure. Supernatant data is the same data 
shown in Figure 19. 
 
 
 After 5 days of vasculogenesis, hBM-on-a-chip containing the endosteal layer and 
subsequently seeded MSCs and HUVECs were fixed and stained to characterize the 
presence and localization of cytokines and ECM relevant to the BM niche by microscopy 
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(Figure 21). CXCL12 and SCF were both found to be expressed by perivascular and 
endothelial cells. Fibronectin was observed to be present in the “central marrow” space 
outside of the newly formed vasculature. This arrangement of cytokine expression is 




Figure 21. ECM and cytokine expression in hBM-on-a-chip. hBM-on-a-chip 
(EC+MSC+OB) with a fibrin (4 mg/mL) and collagen I (1 mg/mL) co-gel with VEGF (50 
ng/mL, days 1-5) and Ang-1 (100 ng/mL, days 3-5) supplementation. Immunofluorescence 




Figure 22. Expansion of HSPCs in hBM-on-a-chip.(A) Number of HSPCs ((i) individual 
devices and (ii) summary data) in hBM-on-a-chip with ECs only (black), with MSCs (red), 
OBs (blue), and both (green) on days 1, 3, and 5. (B) Fold change number of HSPCs ((i) 
individual devices and (ii) summary data) on days 1, 3, and 5. Data are shown as mean ± 
SEM. (n = 4 devices EC+OB, n = 7 devices EC+MSC +OB, n = 8 devices EC and 
EC+MSC). Data were analyzed using Kruskal-Wallis w/ Dunn’s multiple comparisons 
test. (A) EC vs EC+OB p = 0.0210; EC vs EC+MSC+OB p = 0.0166. (B) EC vs EC+OB 
p = 0.0813; EC vs EC+MSC+OB p = 0.0162. 
 
 
4.2.4 Culture of CD34+ HSPCs in hBM-on-a-chip 
 We next sought to investigate the inclusion of BM HSPCs in the hBM-on-a-chip 
and how MSCs and OBs affected their fate in our BM model. BM CD34+ cells were briefly 
expanded in vitro out of cryo-storage and then loaded into the central channel with 
HUVECs and MSCs. We measured the expansion of the HSPCs via microscopy over the 
5 days of culture during vasculogenesis (Figure 22). On day 1, the number of HSPCs in 
hBM-on-a-chip was not significantly different in MSC and/or OB containing devices 
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(Figure 22A). By day 3 and continuing to day 5, devices without OBs had significantly 
more HSPCs than devices with the endosteal layer. HSPCs culture with ECs and MSCs 
expanded 2.41- and 2.28-fold, respectively, over 5 days, whereas both groups with HSPCs 





Figure 23. HSPC differentiation in hBM-on-a-chip. Quantification of 
immunofluorescence of HSPCs cultured for 5 days in hBM-on-a-chip with ECs only 
(black), with MSCs (red), OBs (blue), and both (green). MFI of (A) PK467 (cell tracker), 
(B) CD34, (C) CD38, and (D) CD45RA. Data are shown with median, quartiles, min and 
max (n = 452 cells for isotype from 1 device, n = 800 cells for EC, n = 907 cells EC+MSC, 
n = 945 cells EC+OB, n = 799 cells EC+MSC+OB pooled from 3 devices). 
 
 
 HSPCs will rapidly differentiate when cultured in vitro. We attempted to measure 
the effect of MSCs and OBs on the differentiation of HSPCs in the hBM-on-a-chip by 
staining for CD34, CD38 and CD45RA (Figure 23). HSPCs were pre-labeled with the 
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membrane dye PKH67 to identify HSPCs for subsequent fluorescence quantification 
(Figure 23A). We observed increased expression of CD34 in the presence of MSCs and/or 
OBs (Figure 23B). Staining of CD38 and CD45RA was consistently at or below the 




Figure 24. Cytokine secretion in the presence of HSPCs. Hematopoietic cytokine 
secretion measured in hBM-on-a-chip with HSPCs and ECs only, with or without MSCs 
and OBs, from device supernatant collected on day 5. Data are shown as mean ± SEM (n 
= 4 devices EC+OB, n = 7 devices EC+MSC+OB, n = 8 devices EC and EC+MSC). Data 
analyzed using Kruskal-Wallis w/ Dunn’s post-hoc test. Significance between groups 
(p<0.05) is indicated in the figure. 
 
 
 Overall, incorporation of HSPCs into hBM-on-a-chip did not affect the trends in 
cytokine secretion (Figure 24). Increased concentrations of IL-11, LIF, and M-CSF were 
measured in OB containing devices. However, we observed increased secretion of IL-6 in 
all groups, including in EC and EC+MSC devices which had previously secreted less IL-6 
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than the OB groups. Increased IL-6 production could be a result of activation of the HSPCs, 
indicating potential incompatibility between the HSPC donors and the HUVEC or MSC 
donors, which were not HLA-matched. 
4.3 Methods 
4.3.1 Previously described methods 
hBM-on-chip were fabricated using the methods described in CHAPTER 3, see the 
following sections: 
 3.3.3 PDMS device fabrication 
 3.3.5 Surface coating of PDMS 
4.3.2 Cell culture 
4.3.2.1 BM MSCs 
 Human BM MSCs (RoosterBio) were initially expanded in hMSC High 
Performance Media Kit (RoosterBio). After initial expansion, MSCs were verified by flow 
cytometry to be CD34-, CD45-, CD73+, CD90+, and CD105+. For subsequent passages, 
MSCs were cultured in αMEM (Sigma Aldrich) supplemented with 10% FBS (Hyclone) 
and 1% Penicillin-Streptomycin (Hyclone). MSCs were cultured at 37 °C and 5% CO2. 
MSCs were used up to passage 6. 
4.3.2.2 Human umbilical vein endothelial cells (HUVECs) 
 Pooled HUVECs (Lonza) were cultured in EGM-2MV (Lonza) on 0.1% bovine 
gelatin (Sigma-Aldrich) coated TCPS at 37 ºC and 5% CO2. HUVECs were used up to 
passage 8. 
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4.3.2.3 Human bone marrow CD34+ hematopoietic stem and progenitor cells (HSPCs) 
 Human BM CD34+ cells (Lonza) were expanded for 5 days prior to use in Stemline 
II (Sigma-Aldrich) supplemented with 100 ng/mL SCF, TPO, and G-CSF (Peprotech) at 
37 ºC, 5% CO2. 
4.3.3 Osteogenesis in hBM-on-a-chip 
 For the formation of the endosteal niche, MSCs were seeded within the central gel 
channels of devices at a density of 4x105 cells/mL. Cells were cultured within the devices 
for 21 days in αMEM osteogenic media (10% FBS, 1% penicillin-streptomycin, 10 mM 
β-glycerophosphate (Sigma-Aldrich), 50 µM ascorbic acid (Sigma-Aldrich), and 100 nM 
dexamethasone (Sigma-Aldrich)) with daily media exchange. 
4.3.4 Alizarin red and von Kossa staining and quantification 
 Osteogenic devices were washed with PBS, fixed with 4% formaldehyde in PBS 
for 15 minutes, and then washed with PBS. For Alizarin red staining, devices were washed 
twice with DI H2O and then stained for 5 minutes with 2% alizarin red (Sigma-Aldrich) in 
DI H2O [pH 4.1-4.3]. Alizarin red stain was removed by several washes with DI H2O, until 
liquid was clear. For von Kossa staining, devices were washed twice with DI H2O and then 
stained with 1% silver nitrate (Acros Organics) in DI H2O under a UV lamp for 15 minutes. 
Devices were washed twice with DI H2O and then incubated in 5% sodium thiosulfate 
(Acros Organics) in DI H2O for 5 minutes. Devices were then washed with DI H2O until 
liquid was clear.  
 Stained devices were imaged using a Lionheart FX (BioTek Instruments). Color 
brightfield images were analyzed using open-source software ImageJ [130,131]. The red 
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and green channels were used for von Kossa and Alizarin, respectively, to measure mean 
intensity and percent area. 
4.3.5 Vasculogenesis in hBM-on-a-chip 
 Vasculogenesis in central gel channel was accomplished using previously reported 
approaches [168,169]. Briefly, HUVECs (12x106 cells/mL) and MSCs (6x105 cells/mL) 
were suspended in EBM-2MV supplemented with thrombin (4 U/mL) (Sigma-Aldrich). A 
solution of fibrinogen (8 mg/mL) (Sigma-Aldrich) and collagen I (2 mg/mL) (Corning) in 
PBS was loaded into a central gel channel reservoir. The HUVEC/MSC cell suspension 
was added to fibrinogen solution (1:1) and mixed thoroughly. (Final cell suspension: 
HUVECs (6x106 cells/mL), MSCs (3x105 cells/mL), thrombin (2 U/mL), fibrinogen (5 
mg/mL)), collagen I (1 mg/mL). Immediately, the MSC/HUVEC cell suspension was 
withdrawn from the opposite central gel port, drawing the cell suspension through the 
central gel channel. Devices were then incubated for 15 minutes at 37 ºC, 5% CO2 to allow 
the fibrin gel to form. EBM-2MV was added to a reservoir on each side of gel channel and 
pulled through media channel, into connecting reservoir by using a micropipette to create 
negative pressure in the connecting 1-mm port. Cells were cultured with daily media 
exchange for 5 days to allow for vasculogenesis. Media was supplemented with VEGF (50 
ng/mL) on all days and angiopoietin-1 (Ang-1) (100 ng/mL) (Peprotech) on days 3, 4, and 
5. 
4.3.6 Perfusion 
 To visualize perfusion of microvasculature, 70 kDa dextran-FITC (Sigma-Aldrich) 
was flowed through the media channel on one side of the device. After 5 days of 
vasculogenesis, media was aspirated from all hBM-on-a-chip media ports (EC+MSC) and 
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replaced with 50 µL of 10 µg/mL dextran-FITC in EGM-2MV in two, connected media 
ports. Devices were immediately imaged using a Lionheart FX (BioTek Instruments) 
microscope to visualize the flow of dextran through the central channel of the device. 
4.3.7 Cytokine and ECM immunofluorescence staining and microscopy 
 Staining procedure for devices was adapted from Chen et al 2017 [170]. Devices 
were washed with PBS, fixed with 4% formaldehyde (ThermoFisher), and permeabilized 
with 0.1% Triton X-100. Prior to staining, cells were blocked with 5% BSA, 3% goat serum 
in PBS. Primary antibodies were diluted (typically 1:100) in blocking buffer and devices 
were stained overnight at 4 ºC. Devices were then washed with 0.1% BSA in PBS and 
stained with secondary antibodies (typically 1:200) diluted in wash buffer for 3 hours at 
RT. Devices were washed with wash buffer and then stained with phalloidin AF647 (1:40). 
Devices were imaged using a spinning disk confocal microscope (PerkinElmer). 
4.3.8 Vascular network analysis 
 Devices stained with Alexa Fluor 647 anti-human CD31 (BioLegend) and Alexa 
Fluor 594 Phalloidin (ThermoFisher) were imaged using a Lionheart FX (BioTek 
Instruments). Images were processed using open-source software ImageJ and contrast 
corrected images were analyzed using AngioTool [185] to measure percent area and total 
network length. 
4.3.9 Multiplex cytokine detection 
 Media was collected from devices at designated time by collecting media from one 
side of device, waiting for 5 minutes to allow for gravity driven flow through the device 
and then collection of all media from reservoirs. Device media was immediately stored on 
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ice and then flash frozen in liquid N2 for storage prior to analysis. Samples were thawed 
on ice prior to detection and analysis using LEGENDplex human hematopoietic stem cell 
panel (BioLegend), according to manufacturer’s protocol. 
4.3.10 Culture of CD34+ BM HSPCs in hBM-on-a-chip 
 BM CD34+ HSPCs were labelled with PKH67 green fluorescent cell stain (Sigma-
Aldrich) and loaded at a final concentration of 3x105 (20:1 HUVEC:HSPC ratio, 6x105 
HSPCs/mL in thrombin cell suspension prior to mixing with fibrinogen). This 
concentration results in ~500 HSPCs within the central channel. Devices were imaged on 
days 1, 3, and 5 after loading using a Lionheart FX (BioTek Instruments). Images were 
analyzed using Gen5 (BioTek Instruments) to count the number of HSPCs and progenitors 
at each time point. 
4.3.11 HSPC surface marker staining, imaging, and quantification 
 After 5 days of culture, devices were washed with PBS and fixed with 4% 
formaldehyde (ThermoFisher). Prior to staining, cells were blocked with 5% BSA, 3% goat 
serum in PBS. Primary antibodies were diluted (see Appendix C) in blocking buffer, 
devices were stained overnight at 4 ºC, and then washed with 0.1% BSA in PBS. Samples 
were imaged using a spinning disk confocal microscope (PerkinElmer) and expression of 
surface markers were quantified using Volocity software (PerkinElmer). 
4.3.12 Statistical Analysis 
 Sample sizes and statistical methods are indicated in the figure captions and 
individual data points are shown. GraphPad Prism was used for statistical analysis. 
Normality of samples were tested using Shapiro-Wilk normality test. If all samples in an 
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experiment passed normality test, one-way ANOVA with Tukey’s multiple comparison 
test was used. If a sample did not pass normality test, Kruskal-Wallis with Dunn’s multiple 
comparison test was used.  
4.4 Discussion 
 We have shown that by using the microfluidic devices designed in CHAPTER 3 
we are able to recreate basic features of the endosteal and perivascular niches of human 
BM. This is a unique example of a defined, in vitro culture platform that combines both 
microenvironments in a single system. While there are numerous previously reported 
platforms for recreating the BM microenvironment, many of these only incorporate single 
cell types in co-cultures and more complex models require lengthy development as ectopic 
implants in animal models [104,150]. As evidence mounts that suggests that the endosteal 
and perivascular niches play unique roles in the regulation of normal and diseased states of 
hematopoiesis in, a complex, multi-niche culture platform is needed to recapitulate the 
complexity of BM tissue. The hBM-on-a-chip presented here is one of few examples of 
such an approach [103]. 
 We have demonstrated that an endosteal niche can be formed within the hBM-on-
a-chip through a 21-day differentiation of MSCs and that, due to the design of the device 
optimized in CHAPTER 3, subsequently we can load ECs, MSCs, and HSPCs on top of 
this endosteal layer in order to form microvasculature. Cytokine expression is dependent 
on the inclusion of stromal cells and is elevated when OBs are present. We have also 
showed that BM HSPCs culture in hBM-on-a-chip have increased levels of expansion in 
the absence of OBs, however CD34 expression (and stemness) is maintained when OBs 
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are present in the culture. Functionally, the inclusion of the endosteal layer results in a 
different microenvironment for hematopoietic cells. 
 Further characterization of the hBM-on-a-chip and HSPC culture would expand our 
understanding of the microenvironment being created. The expression of many cytokines, 
ECM proteins, and signaling molecules that are relevant to specific hematopoietic 
functions that could be studied in hBM-on-a-chip. Additionally, with the many 
hematopoietic progenitors that could be arising within the culture, the hBM-on-a-chip 
should be further defined to understand the hematopoietic and BM microenvironment 
being created.  
 There are also several improvements that could be made to hBM-on-a-chip to 
facilitate its use and to better and more reliably replicate the BM microenvironment. 
Currently, the time required to create the endosteal niche is lengthy and shortening this step 
would greatly improve the potential utility of the approach. There are several commercially 
available differentiation media compositions available that could, in theory, shorten the 
culture time while maintaining the phenotypic results. One significant challenge with the 
device in its current design is the consistency of formation of perfusable vasculature. Due 
to the prolonged culture, prior to loading of the fibrin-collagen co-gel, the hydrogel does 
not reliably adhere to the PDMS surface (likely because proteins have already adsorbed to 
the surface) which caused slight delamination that allowed for fluid flow around the 
hydrogel and not through the newly formed vasculature. Achieving consistent adhesion of 
the hydrogel to the device structure, through chemical modification or by other means is 
necessary for translation of this platform into a preclinical setting where increased 
consistency is necessary. Finally, the device is, while complex, a relatively simple model 
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of the BM microenvironment, inclusion of additional stromal and mature hematopoietic 
cell types could improve upon the relevance to native tissue.  
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CHAPTER 5. AIM 2A: MOBILIZATION OF HSPCS 
5.1 Introduction 
Although HSPCs are predominately located and maintained within the BM niche 
by the CXCL12-CXCR4 signaling axis, in normal physiological conditions HSPCs can 
also be found in peripheral blood in small numbers. It is thought that a constant low 
frequency flux of HSPCs into the periphery and back into BM is required for normal 
developmental processes and hematopoietic maintenance [186]. It is unlikely that HSPCs 
occupy a single, static niche, they are likely migrating within the BM as well as leaving 
and reentering the BM at a low rate [186,187]. Clinical interventions have been developed 
to significantly increase the number of HSPCs in peripheral blood so that they can be 
collected by apheresis for subsequent autologous or, less frequently, allogeneic stem cell 
transplantation. This is a common therapeutic approach for patients with multiple myeloma 
or other hematologic malignancies, where HSPCs are mobilized, collected, and then 
reinjected to reconstitute the hematopoietic system after chemotherapeutic or radiologic 
ablation of the malignancy (and subsequently, the remaining hematopoietic cells) [188]. 
G-CSF has long been used in conjunction chemotherapy (typically cyclophosphamide) to 
mobilize BM HSPCs, however it is not effective in all patients. Previous chemotherapy or 
radiotherapy regimens, age, and disease burden have all been considered as clinical 
variables that may cause poor mobilization [189-191]. Over the last 20 years, AMD3100 
(Mozobil, Plerixafor) has been developed and is now the second FDA approved mobilizing 
drug and is used, although at a significant increase in cost, as a second line treatment for 
patients who have failed G-CSF plus chemotherapy mobilization [192].  
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Figure 25. Mobilization of HSPCs from BM microenvironment. Mobilization of 
HSPCs from BM microenvironment relies on disruption of the CXCL12-CXCR4 signaling 
axis. AMD3100 (or plerixafor) is a CXCR4 antagonist and directly blocks the binding of 
CXCL12 by surface expressed CXCR4 on HSPCs, resulting in egress of HSPCs from the 
BM niche. The mechanism of G-CSF mobilization is less clear. It has been reported that 
G-CSF treatment results in elevated expression of proteolytic enzymes by osteoblasts, 
osteoclasts and BM macrophages that, in turn, degrade CXCL12 and chemokine receptors. 
Alternatively, it has been proposed that G-CSF mobilization is a result of proliferation of 
BM HSPCs and not specifically migration out of BM. 
 
 
The specific mechanism of G-CSF mobilization is unknown. G-CSF is expressed 
endogenously and acts on several hematopoietic and stromal cells in BM resulting in a 
spectrum of physiologic outcomes, including expansion of hematopoietic progenitors and 
the differentiation of granulocytes. Specific to mobilization, G-CSF is believed to stimulate 
macrophages, osteoblasts, and osteoclasts to induce upregulation of proteolytic enzymes 
(MMP9, cathepsins, etc.) that subsequently degrade CXCL12 and potentially surface 
bound VLA-4 and CXCR4 on HSPCs [193-198]. By decreasing both the free CXCL12 and 
HSPCs ability to bind the chemokine, G-CSF may disrupt the signaling axis that keeps 
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HSPCs in the BM, thus increasing the percentage of HSPCs in peripheral blood. Because 
G-CSF signals through resident cells and does not directly interrupt the chemokine 
signaling, onset of mobilization by G-CSF is relatively slow, taking greater than 24 hours 
to reach maximum mobilization [187]. The effects of G-CSF mobilization are additive 
when additional doses are given, which has led to the current clinical protocol of 4-6 days 
of G-CSF treatment prior to the initial collection of HSPCs from peripheral blood 
[187,188,199]. Aside from direct disruption of the CXCL12-CXCR4 signaling axis, there 
is a competing explanation for G-CSF mobilization. G-CSF induces proliferation of 
hematopoietic cells and it has been observed to increase the number of HSPCs in the BM 
after administration. As a result, the increase in HSPCs in peripheral blood could simply 
be a byproduct of increased total numbers of HSPCs in all compartments. 
In contrast, the mechanism of mobilization by AMD3100 is known and specific. 
AMD3100 is an antagonist of CXCR4 and directly competes with CXCL12 for binding. 
CXCR4+ hematopoietic cells are then no longer able to respond to the CXCL12 gradient 
that maintains higher populations in the BM, and this causes the number of HSPCs in 
peripheral blood increases. Consequently, the kinetics of mobilization are much faster than 
G-CSF, with increased numbers of HSPCs observed in peripheral blood as early as 30 
minutes post injection [200]. Not only is AMD3100 a faster mobilizer, but when used in 
conjunction with G-CSF, AMD3100 mobilizes more CD34+ cells and has more predictable 
kinetics than G-CSF alone [199,201-203]. There is some debate on whether AMD3100 is 
truly mobilizing HSPCs from the BM. It is possible that administration of AMD3100 
results in binding of CXCR4 receptors on hematopoietic cells already in peripheral blood 
and prevents the migration of these cells back to BM and heightened concentrations of 
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CXCL12. As a result, the number of HSPCs in peripheral blood increases as BM HSPCs 
leave the BM niche at a normal rate but can no longer migrate back to the tissue. 
In addition to G-CSF and AMD3100, a number of potential mobilizing agents, 
including Groβ, IL-8, and sphingosine-1-phosphate (S1P) have been tested in preclinical 
models, although none are currently approved for clinical mobilization [204,205]. Groβ 
and IL-8 are believed to have the same mechanism of action, where MMP-9 expression is 
increased in BM resident neutrophils, resulting in an indirect disruption of the CXCL12-
CXCR4 signaling axis [190,206,207]. Under normal physiologic conditions, S1P acts as a 
chemoattractant for BM HSPCs, causing egress from BM in response to injury [205,208].  
Here, we assess the ability of the hBM-on-a-chip to study the mobilization of 
HSPCs and its potential to be a screening tool for novel mobilization agents. Currently 
preclinical research is restricted to animal models [209] and the hBM-on-a-chip could 
potentially be used to screen novel therapeutics on a large population of human samples in 
vitro or in a patient specific BM model to assess an individual’s mobilization potential.  
5.2 Results 
5.2.1 Effect of G-CSF and AMD3100 on cytokine expression in hBM-on-a-chip 
To investigate the effect of mobilizing agents on the BM microenvironment in 
hBM-on-a-chip, devices containing OBs, MSCs, and ECs were treated with G-CSF and 
AMD3100 for 24 hours after 5 days of vasculogenesis. The change in cytokine secretion, 
from 0 hours (pre-treatment) to 24 hours was measured for a panel of hematopoietic 
cytokines (Figure 26). IL-6, IL7, IL-11, LIF, and M-CSF were detected in device 
supernatant, while CXCL12, IL-3, IL-15, IL-34, GM-CSF, FLT3L, and SCF were below 
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the detection limit of the assay. Of the cytokines that were detected, expression was 
relatively consistent between 0 and 24 hours, with a moderate increase in IL-6 and M-CSF 
measured. No significant difference was found between an untreated control and devices 
treated with 10 ng/mL or 100 ng/mL of G-CSF or AMD3100, suggesting that in the 





Figure 26. Effect of mobilizing agents on cytokine secretion without HSPCs. Change 
in hematopoietic cytokine measured in hBM-on-a-chip (without HSPCs) supernatant 
before (0 hours) and 24 hours after devices were untreated (white) or treated with 10 ng/mL 
G-CSF (light blue), 100 ng/mL G-CSF (100 ng/mL), 10 ng/mL AMD3100 (light green), 
or 100 ng/mL AMD3100 (dark green). Data are shown as mean ± SEM (n = 5 devices). 
Data analyzed using Kruskal-Wallis with Dunn’s multiple comparisons test. No 
significance between groups (p < 0.1).  
 86 
 
Figure 27. CXCL12 expression after 24-hour treatment with AMD3100 or G-CSF. 
(A) Immunofluorescence staining of CD31 (red), F-actin (green), and CXCL12 (grey) 24 
hours after hBM-on-a-chip (EC+MSC+OB) were untreated or treated with G-CSF (10 
ng/mL) or AMD3100 (10 ng/mL). Scale bar: 50 µm. (B) Quantification of CXCL12 
fluorescence staining (i) by individual ROI and (ii) by device. Data are shown as mean ± 
SEM (n = 5 ROIs from 1 device isotype, n = 10 ROIs from 2 devices untreated, n = 15 
ROIs from 3 devices AMD3100 and G-CSF). Data analyzed using Kruskal-Wallis w/ 
Dunn’s multiple comparisons test. No significance between experimental groups. 
 
 
 Mobilization of HSPCs relies on the disruption of the CXCL12-CXCR4 signaling 
axis. Because CXCL12 was not detectable using a bead based multiplex assay, standard 
ELISA, or a modified ELISA an alternative measurement method was needed to determine 
whether G-CSF or AMD3100 was modulating the CXCL12 expression. 
Immunohistochemistry was chosen to measure the relative expression (see Appendix B for 
more detail). hBM-on-a-chip (EC+MSC+OB) were stained for CXCL12, CD31 (EC 
marker), and F-actin (all cells) (Figure 27A). CXCL12 was expressed by ECs and 
perivascular stromal cells. While AMD3100 (10 ng/mL) did not affect CXCL12 
expression, we observed a G-CSF (10 ng/mL) decreased in measured CXCL12 in a subset 
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Figure 28. Measuring mobilization in hBM-on-a-chip. (A) To observe the 
“mobilization” of HSPCs, we imaged devices 13 times over a 24-hour period. After the 
first imaging session, media was collected from the devices and it was exchanged for 
untreated media or media supplemented with mobilizing agents. During each imaging 
session, devices were imaged 4 times in 5-minute intervals. Cells were tracked during each 
imaging session to measure the track length and displacement at each time point. Scale bar: 
20 µm. (B) Track length and (C) displacement over 24 hours in untreated devices. (B) and 
(C): data (n = 853-1236 tracked cells per time point pooled from 7 devices) are shown with 
median (red), quartiles (black), and 0-hour median (gray line).  
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5.2.2 Mobilization of CD34+ BM by G-CSF and AMD3100 
In order to measure the mobilization of HSPCs in hBM-on-a-chip, we designed an 
experimental assay where devices were imaged every 2 hours over a 24-hour period after 
treatment with mobilizing agents (Figure 28A). During each imaging session, devices were 
imaged 4 times in 5-minute intervals and these images were used to track cell movement 
and measure the length and displacement at discrete points in time during the 24-hour 
period. Untreated samples showed relatively steady movement of HSPCs when measured 
by either the length (Figure 28B) or displacement (Figure 28C) over 24 hours. 
 Treatment of hBM-on-a-chip (EC+MSC+OB+HSPC) with 10 ng/mL or 100 ng/mL 
G-CSF resulted in a moderate increase in the relative length and displacement of HSPCs 
at the lower concentration (Figure 29). The absolute, measured values of cell movement 
show little, if any, difference between untreated and G-CSF treated samples. However, 
when length and displacement are normalized and the fold change is calculated relative to 
the 0-hour baseline, differences between the groups emerge. After treatment with 10 ng/mL 
G-CSF, HSPCs had an increased track length and displacement between approximately 2-
14 hours post-treatment. Untreated and samples mobilized with 100 ng/mL G-CSF did not 
show any sustained increase in HSPC movement, either measured by length or 
displacement, but instead had a steady decrease from the peak at the 0-hour baseline 
measurement. Mobilization using AMD3100 at low doses of 1 ng/mL and 10 ng/mL did 
not result in any increased movement of HSPCs relative to the untreated control (Figure 
30).   
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Figure 29. HSPC mobilization by G-CSF in hBM-on-a-chip. hBM-on-a-chip 
(HSPC+EC+MSC+OB) were untreated (black) or treated with 10 ng/mL G-CSF (light 
blue) or 100 ng/mL G-CSF (dark blue) and movement of HSPCs was measured over 24-
hours. (A) Aggregate geometric mean track length, (B) sample geometric mean length, (C) 
aggregate geometric mean displacement, and (D) sample geometric mean displacement are 
represented as (i) absolute values and (ii) fold change for each sample. (A and C) Data are 
shown as (i, ii) geometric mean (i) ± 95%CI (n = 1627-2835 cells per time point pooled 
from 7-8 devices). (B and D) Data are shown as mean of geometric means ± SEM (n = 7 
devices untreated, n = 8 devices 10 and 100 ng/mL G-CSF). Untreated data are the same 
as data shown in Figure 28B, C.   
 90 
 
Figure 30. HSPC mobilization by AMD3100 in hBM-on-a-chip. hBM-on-a-chip 
(HSPC+EC+MSC+OB) were untreated (black) or treated with 1 ng/mL AMD3100 (light 
green) or 10 ng/mL AMD3100 (dark green) and movement of HSPCs was measured over 
24-hours. (A) Aggregate geometric mean track length, (B) sample geometric mean length, 
(C) aggregate geometric mean displacement, and (D) sample geometric mean displacement 
are represented as (i) absolute values and (ii) fold change for each sample. (A and C) Data 
are shown as (i, ii) geometric mean (i) ± 95%CI (n = 1591-2246 cells per time point pooled 
from 7 devices). (B and D) Data are shown as mean of geometric means ± SEM (n = 7 
devices). Untreated data are the same as data shown in Figure 28B, C.  
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5.2.3 Role of endosteal niche in mobilization 
 To determine whether the endosteal niche affected mobilization by G-CSF or lack 
of mobilization by AMD3100, we measured mobilization in hBM-on-a-chip with OBs (a 
vascularized endosteal niche model) and without OBs (a perivascular niche model). Similar 
to the previous, dosing experiment (Figure 29), with an endosteal niche present (+OB) 
devices treated with 10 ng/mL G-CSF had increased HSPC track length from 
approximately 2-14 hours post-treatment when compared to the untreated +OB control 
(Figure 31). Without an endosteal niche, there was no trend in increased track length or 
displacement when compared to the untreated -OB control. Again, there was no evidence 
of increasing length or displacement of HSPCs when treated with AMD3100 in the 
presence or absence of the endosteal niche (Figure 32). 
5.2.4 High dose mobilization with AMD3100 
 To investigate whether the lack of mobilization in response to AMD3100 at doses 
of 1 ng/mL and 10 ng/mL, we tested a higher range of concentrations for mobilization 
potential (Figure 33). At 100 ng/mL, AMD3100 substantially increased HSPC track length 
from 2-4 hours post-treatment in the presence of the endosteal niche (+OB). However, the 
untreated +OB control also showed increased movement of HSPCs during this time frame, 




Figure 31. Effect of endosteal niche on G-CSF mobilization. hBM-on-a-chip with OBs 
(solid lines) and without OBs (dotted lines) were treated with 10 ng/mL G-CSF (light blue) 
or were untreated (black) and movement of HSPCs was measured over 24-hours. (A) 
Aggregate geometric mean track length, (B) sample geometric mean length, (C) aggregate 
geometric mean displacement, and (D) sample geometric mean displacement are 
represented as (i) absolute values and fold change for samples (ii) without OBs and (iii) 
with OBs. (A and C) Data are shown as () geometric mean (i) ± 95%CI (n = 746-1815 cells 
pooled from 3-6 devices). (B and D) Data are shown as mean of geometric means ± SEM 
(n = 3 devices +OB untreated, n = 5 devices –OB untreated, n = 6 devices –OB and +OB 
+GCSF).   
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Figure 32. Effect of endosteal niche on AMD3100 mobilization. hBM-on-a-chip with 
OBs (solid lines) and without OBs (dotted lines) were treated with 10 ng/mL AMD3100 
(green) or were untreated (black) and movement of HSPCs was measured over 24-hours. 
A) Aggregate geometric mean track length, (B) sample geometric mean length, (C) 
aggregate geometric mean displacement, and (D) sample geometric mean displacement are 
represented as (i) absolute values and fold change for samples (ii) without OBs and (iii) 
with OBs. (A and C) Data are shown as () geometric mean (i) ± 95%CI (n = 746-1498 cells 
pooled from 3-5 devices). (B and D) Data are shown as mean of geometric means ± SEM 




Figure 33. High dose AMD3100 mobilization of HSPCs. hBM-on-a-chip with OBs 
(solid lines) and without OBs (dotted lines) were treated with 1 µg/mL (light green), 10 
µg/mL (green), 100 µg/mL AMD3100 (dark green) or were untreated (black) and 
movement of HSPCs was measured over 24-hours. (A) Aggregate geometric mean track 
length, (B) sample geometric mean length, (C) aggregate geometric mean displacement, 
and (D) sample geometric mean displacement are represented as (i) absolute values and 
fold change for samples (ii) without OBs and (iii) with OBs. (A and C) Data are shown as 
() geometric mean (i) ± 95%CI (n = 265-787 tracked cells per time point pooled from 3-4 
devices). (B, D) Data are shown as mean of geometric means ± SEM (n = 3 devices –OB 
100 µg/mL, +OB 100 µg/mL, n = 4 devices all other groups).  
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5.2.5 Mobilization with G-CSF and bortezomib 
 Mobilization of G-CSF is often done after or during chemotherapeutic regimes and 
prior treatment with chemotherapy. High dose chemotherapy (often with 
cyclophosphamide) in conjunction with G-CSF is the standard clinical mobilization 
protocol; however, patients that have had prior chemotherapy regimens can also be at risk 
for poor mobilization. We treated hBM-on-a-chip (HSPC+EC+MSC±OB) with 
bortezomib (BTZ), a protease inhibitor used to treated multiple myeloma that has been 
implicated in improving mobilization via disruption of VLA-4/VCAM-1 interactions 
between HSPCs and the BM microenvironment [210]. To investigate whether bortezomib 
induced mobilization of HSPCs or inhibited G-CSF mobilization, we treated hBM-on-a-
chip with bortezomib, with and without simultaneous G-CSF treatment, both in devices 
with (+OB) and without (-OB) the endosteal niche (Figure 34). Bortezomib alone did not 
induce mobilization of HSPCs in devices with or without the endosteal niche as measured 
by track length (Figure 34A,B) and displacement (Figure 34C,D). Surprisingly, when 
samples were mobilized with bortezomib and G-CSF (at the same dose as in previous 
experiments (Figure 29, Figure 31), we also did not see any evidence of increase in length 
or displacement of HSPC movement. This suggests that bortezomib inhibited G-CSF 





Figure 34. Mobilization with G-CSF with simultaneous bortezomib treatment. hBM-
on-a-chip with OBs (solid lines) and without OBs (dotted lines) were treated with 100 nM 
bortezomib (BTZ) (red), 100 nM BTZ and 10 ng/mL G-CSF (blue) or were untreated 
(black) and movement of HSPCs was measured over 24-hours. (A) Aggregate geometric 
mean track length, (B) sample geometric mean length, (C) aggregate geometric mean 
displacement, and (D) sample geometric mean displacement are represented as (i) absolute 
values and fold change for samples (ii) without OBs and (iii) with OBs. (A and C) Data are 
shown as () geometric mean (i) ± 95%CI (n = 634-1004 tracked cells per time point pooled 
from 5-6 devices). (B, D) Data are shown as mean of geometric means ± SEM (n = 6 
devices –OB and +OB untreated, n = 5 devices all other groups).  
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5.3 Methods 
5.3.1 Previously described methods 
hBM-on-chip were fabricated and cultured using the methods described in 
CHAPTER 3 and CHAPTER 4, see the following sections: 
3.3.3.3 Version 2.0 device fabrication 
3.3.5 Surface coating of PDMS 
4.3.2 Cell culture 
4.3.3 Osteogenesis in hBM-on-a-chip 
4.3.5 Vasculogenesis in hBM-on-a-chip 
4.3.10 Culture of CD34+ BM HSPCs in hBM-on-a-chip 
5.3.2 Measuring CXCL12 by IHC 
Staining procedure for devices was adapted from Chen et al 2017 [170]. Devices 
were washed with PBS, fixed with 4% formaldehyde (ThermoFisher), and permeabilized 
with 0.1% Triton X-100. Prior to staining, cells were blocked with 5% BSA, 3% goat serum 
in PBS. Primary antibody was diluted (1:100) in blocking buffer and devices were stained 
overnight at 4 ºC. Devices were then washed with 0.1% BSA in PBS (wash buffer) and 
stained with secondary antibody (1:200) diluted in wash buffer for 3 hours at RT. Devices 
were washed with wash buffer and then stained with Phalloidin AF647 (1:40).  
5.3.3 G-CSF, AMD3100 Bortezomib treatment 
After 5 days vasculogenesis, hBM-on-a-chip devices were treated with G-CSF 
(Peprotech), AMD3100 (Sigma Aldrich) and/or bortezomib (Sigma-Aldrich). G-CSF, 
AMD3100, bortezomib were diluted to indicated concentrations in EGM-2MV (Lonza) 
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[211]. Media was aspirated from media reservoirs of hBM-on-a-chip and replaced with 50 
µL per reservoir (200 µL total per device) by adding 100 µL to one side of the device and 
allowing the media to flow through to the connecting reservoir.  
5.3.4 Multiplex cytokine detection 
 Device media was collected at 0 hours (immediately prior to treatment with G-CSF 
or AMD3100) and 24 hours after treatment. Media was collected from devices at 
designated time by collecting media from one side of device, waiting for 5 minutes to allow 
for gravity driven flow through the device and then collection of all media from reservoirs. 
Device media was immediately stored on ice and then flash frozen in liquid N2 for storage 
prior to analysis. Samples were thawed on ice prior to detection and analysis using 
LEGENDplex human hematopoietic stem cell panel (BioLegend), according to 
manufacturer’s protocol. 
5.3.5 Measuring mobilization of HSPCs 
After 5 days of culture, hBM-on-a-chips were imaged periodically to measure the 
“mobilization” of CD34+ HSPCs. Baseline measurements were made at 0 hours, after 
which supernatants were collected and was replaced with media supplemented with 
mobilizing agents at indicated concentrations. Samples were imaged at intervals of 2 hours 
for 24 hours for a total of 13 image sessions. During each image session, devices were 
imaged at intervals of 5 minutes for 15 minutes, for a total of 4 time points. Samples were 
imaged using a Cytation 3 (BioTek Instruments) and automated imaging of multiple plates 
was achieved using a BioSpa 3 (BioTek Instruments). Image sequences were imported into 
Volocity software (PerkinElmer), cells were tracked within each image session, and the 
length and displacement of individual cells were measured at each time point.  
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To represent the mobilization data, we show both the aggregate population 
geometric mean and the mean of sample geometric means. The distribution of cell track 
length and displacement is lognormal (Figure 28B,C), therefore the geometric mean is a 
more appropriate representative statistic of the population than the arithmetic mean. 
Geometric mean length and displacement were measured for both the population of all 
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And the geometric mean was calculated for each individual sample, j, to quantify the 
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5.4 Discussion 
 In this chapter we have investigated the effect of G-CSF and AMD3100 on the 
surrogate BM microenvironment in the hBM-on-a-chip and we have developed a potential 
method for studying the mobilization of HSPCs in the BM mimic devices. 
 The mobilization of stem cells from BM requires the disruption of the multifaceted 
biochemical signaling that maintains HSPCs in the BM compartment. Although standard 
regimens (high dose chemotherapy and G-CSF) and rapid mobilizers (AMD3100) are 
successful in most patients, there are a subset of patients who still fail to mobilize and there 
are few clinically approved options beyond those mentioned above [191]. An in vitro 
microenvironment that can mimic the native tissue’s response to mobilization would be 
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useful in preclinical evaluation of novel compounds and, potentially, for patient specific 
screening of possible regimens. 
 Due to the complex nature of the mobilization process, most preclinical studies of 
are performed in animal models, although there are a few examples of in vitro methods. 
Transwell migration assays have been used to study agents that the disrupt HSPC migration 
toward CXCL12 or other chemokines, and to study agents that are chemokines themselves 
and work through competitive signaling [212]. There are even fewer examples of 3D 
culture models that have been used to study the disruption of CXCL12/CXCR4 signaling. 
One such example is the hydrogel co-culture of HSPCs with MSCs, where treatment with 
AMD3100 induced the migration of HSPCs out of the hydrogel into the culture media 
[213]. To our knowledge, no in vitro culture systems that incorporate the perivascular niche 
have been used to study the disruption of the HSPC chemokine signaling. 
 We first investigated the effects of G-CSF and AMD3100 on cytokine secretion in 
hBM-on-a-chip. We found no significant difference in the expression of cytokines that 
were measurable within the device supernatant. Because CXCL12 was not detectable, we 
attempted to quantify its expression using immunohistochemistry (see Appendix B for 
more details). As expected, AMD3100, which inhibits CXCR4 specifically, did not affect 
CXCL12 expression. Although there was no significant difference in CXCL12 expression, 
we did observe a substantial decrease in expression in a subset of the devices treated with 
G-CSF. It is unclear if the decrease in CXCL12 expression we observed is characteristic 
of a population of hBM-on-a-chips, that only a subset of devices will have decreased 
CXCL12 expression due to an inherent difference in the device composition (cells, 
material, etc.) that has gone unnoticed. Further study is needed to fully understand this 
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response. 
 To measure the mobilization of HSPCs in hBM-on-a-chip, we developed a protocol 
that allowed for the periodic measurement of cell movement over a 24-hour period. We did 
so because we did not anticipate HSPCs would be drawn out of the hBM-on-a-chip, 
because there was no supplemented chemokine or existing gradient within the device that 
would direct the HSPCs in a specific direction. Rather, we hypothesized that mobilization 
would disrupt local signaling that was restricting HSPC movement and would therefore 
lead to an increase in either the magnitude or displacement of migration during a given 
time period.  
 Mobilizing with AMD3100, we did not see any change in migration at low doses. 
Although the result was obscured by high fold change in control, untreated samples, we 
measured a substantial increase in movement with a high dose of AMD3100 (100 µg/mL) 
2-4 hours after treatment, which merits attention for future studies. Mobilizing the HSPCs 
with G-CSF, we observed a dose specific response that lead to increased total length of 
migration and displacement over approximately a 14-hour period compared with the 0-
hour baseline in both vascularized endosteal niche (+OB) and perivascular (-OB) hBM-on-
a-chip devices. The mechanism of G-CSF mobilization is believed to go through any 
number of BM resident cells (neutrophils, osteoblasts, osteoclasts, macrophages) [193-
196] with MSCs being a notable exception. The potential mobilization observed in samples 
without OBs is curious and, if true, suggests that either MSCs can mediate G-CSF induced 
disruption of CXCL12 signaling or that G-CSF is directly activating increased movement 
in HSPCs. 
 Similarly, the lack of response to G-CSF when co-administered with bortezomib 
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was unexpected. Bortezomib has been shown to mobilize HSPCs independent of and 
additively with other treatments in animal models [210]. Due to the relative simplicity of 
the hBM-on-a-chip, it reasonably could be that a or any number of cell types that are 
necessary for the in vivo response are not present and therefore the model cannot 
recapitulate the effect of the treatment. Similarly, the state of the HSPCs themselves in 
hBM-on-a-chip could deviate the observed response in unexpected ways. 
 While we did observe some effect in response to mobilizing agents, which is 
encouraging for the utility of hBM-on-a-chip for this application, there are many areas for 
improvement. First, there is a significant amount of noise, both between time points and 
between samples, relative to the size of the measured effect that necessitates large sample 
sizes. While we are reasonably confident in our conclusions, it should be noted that the 
untreated samples did exhibit periodic fluctuations in track length and displacement, and it 
should not be discounted that there is a possibility that any effect we observed was random 
noise. Second, as mentioned above, the hBM-on-a-chip in its current iteration is a relatively 
simple model of the BM microenvironment and does not contain many key cell types that 
have been implicated in the mobilization process. Increasing the complexity, while 
decreasing the inter- and intra-device variability is necessary for using hBM-on-a-chip for 
studying HSPC mobilization.  
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CHAPTER 6. AIM 2B: EFFECTS OF RADIATION 
6.1 Introduction 
Ionizing radiation (IR) can cause damage to BM microenvironment and resident 
HSPCs occurs in both accidental and clinical situations [214]. In both cases, exposure to 
IR causes damage to HSPCs and subsequently results in the depletion of mature 
hematopoietic cells, leading to a range of symptoms associated with hematopoietic 
syndrome, and in extreme cases, fatality. At low doses of IR, populations of circulating 
hematopoietic cells decline quickly, within days, but recover weeks after the exposure. At 
higher doses of IR (the LD50 for humans is 4.25 Gy [215]) the acute loss of circulating cells 
never recovers, and the hematopoietic system fails because HSCs in the BM are no longer 
able to generate sufficient progenitor cell populations [216]. Understanding the specific 
impact of IR on HSPCs and the BM niche is important for developing effective 
countermeasures that can allow for the native or transplanted hematopoietic system to 
recover or reconstitute a healthy BM.  
While the direct effects of IR on the hematopoietic system are well characterized, 
the corresponding effects of IR on the HSPC niche and stromal cells in the BM 
compartment are less understood. The specific effects of IR on the BM microenvironment 
can directly lead to damage to hematopoietic cells (e.g. through the production of reactive 
oxygen species [215,217,218]), or they can indirectly damage the hematopoietic system 
(e.g. by the change in expression of proteases or ECM in the BM niche). MSCs, what are 
sometimes referred to as the other BM stem cell, are surprisingly more resistant to the 
effects of IR. MSCs have been observed to resistant to ionizing radiation, possibly 
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providing protection to other radiation damaged cells [219]. Conversely, the activity of 
both osteoblasts and endothelial cells are altered by exposure to IR. Osteoblasts have been 
observed to be downregulated [218,220,221], decreasing the deposition of endosteal matrix 
and possibly, in conjunction with up regulation of osteoclasts, cause loss of bone mass at 
a larger scale[222]. This could lead to the loss of the endosteal niche for specific progenitor 
cell populations that may be counteracted by increased osteogenic differentiation of MSCs 
[223]. Common to radiation damage to all tissue types, the vasculature in BM is damaged 
and blood flow is disturbed [220]. Damage to endothelial cells likely disrupts the 
perivascular niche occupied by HSCs and recovery of this microenvironment is essential 
for the regeneration of the functioning hematopoietic system. 
The effects of radiation have, in the past, been studied mostly in animal models, 
recently organ-on-chip systems have been explored for their potential application in 
radiobiology [224,225]. Using organ-on-chip systems to examine the biologically response 
to radiation exposure not only moves preclinical studies away from animal models, but it 
may better recapitulate the response of human cells in radiation exposure situations. An ex 
vivo, ectopic engineered BM has been used to test the effectiveness of radiation 
countermeasures. Typical countermeasure treatments, like EPO and G-CSF, increased the 
production of hematopoietic cells in the engineered BM and were generally consistent with 
clinical observations [225].  
Cs-137 has been the standard source of ionizing radiation in in vitro and preclinical 
in vivo studies, including the previously discussed examples of organ-on-chips [225]. 
Recently, x-ray radiation sources have been introduced to replace Cs-137 irradiators 
because, since the radiation emission can be turned off, they are much safer instruments 
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for research use. However, the use of PDMS in device fabrication creates a potential 
problem for its application in radiation studies when using an x-ray source irradiator 
because PDMS has been observed to attenuate x-rays, especially during low energy 
exposures [226].  
Here, we use the hBM-on-a-chip to investigate the effects of IR on HSPCs, the BM 





Figure 35. Effects of radiation on BM microenvironment. Ionizing radiation causes cell 
death because of DNA damage to proliferative cells in the BM compartment, HSCs and 
their progenitors suffer increasing amounts of cell death as a function of the radiation dose. 
Osteoblasts have been observed decrease in functionality, leading to loss of bone mass that 
is exacerbated by potential increased osteoclast activity. Endothelial cells undergo 
apoptosis and vascularization of irradiated tissue decreases.  
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6.2 Results 
6.2.1 PDMS attenuation of x-ray radiation 
To determine the x-ray attenuation of hBM-on-a-chip, dosimeters were exposed to 
x-ray radiation doses of 2.5 Gy, 5 Gy, and 10 Gy through the well-plate hBM-on-a-chip 
device and compared to un-shielded, control dosimeters (Figure 30). Dosimeters shielded 
by the device did not show any reduction in dose compared to the control dosimeters. The 
measured dose of radiation was less than the theoretical dose for all three groups. The 
measured dose (both control and PDMS shielded) was 1.73 ± 0.04 Gy, 3.89 ± 0.03 Gy, and 
8.03 ± 0.11 Gy (mean ± SEM) for the 2.5 Gy, 5 Gy, and 10 Gy groups, respectively. This 




Figure 36. PDMS attenuation of x-ray radiation. (A) Measured radiation dose of 
NanoDot® dosimeters exposed to 2.5, 5, or 10 Gy x-ray radiation with (blue) or without 
(white) PDMS shielding. Data is shown as mean (n = 2 dosimeters). (B) Linear regression 
(Equation 5) of grouped (unshielded and PDMS shielded) dosimeter readings (red) used to 
interpolate exposure settings for accurate dosing. Data are shown as mean ± SD (n = 4 
dosimeters). Perfect correlation (y = x) between theoretical and measured dose is shown 
by grey dotted line. 
 
 
Grouping the unshielded control samples and the PDMS shielded samples together, 
linear regression was performed to determine the difference between the theoretical 
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radiation dose and the actual radiation dose measured (Equation 5). 
 𝐷𝐷𝑐𝑐𝑐𝑐𝑒𝑒𝑀𝑀𝑎𝑎𝑎𝑎𝑏𝑏𝑙𝑙𝑎𝑎𝑎𝑎𝑙𝑙 = 0.8108 𝐷𝐷𝑐𝑐𝑐𝑐𝑒𝑒𝑇𝑇ℎ𝑎𝑎𝑝𝑝𝑎𝑎𝑎𝑎𝑏𝑏𝑙𝑙𝑎𝑎𝑎𝑎𝑙𝑙 − 0.1349 ;𝑅𝑅2 = 0.9987 (5) 
Exposure settings were subsequently adjusted to account for discrepancy between the 
irradiator’s exposure rate and the measured doses. 
6.2.2 Effect of radiation on hBM-on-a-chip microenvironment 
To investigate the effect of ionizing radiation on the BM microenvironment in 
hBM-on-a-chip, after 5 days of vasculogenesis, devices containing OBs, MSCs, and ECs 
were exposed to 0 Gy, 2.5 Gy, 5 Gy, or 10 Gy x-ray irradiation. Device supernatant was 
collected at 0 hours (pre-treatment) and 24 hours radiation exposure. To measure 
cytotoxicity because of radiation, the change in lactate dehydrogenase (LDH) activity of 
the supernatant after irradiation was measured (Figure 37). Although we did not measure 
a significant increase in LDH activity, the LDH activity in devices exposed to 5 Gy and 10 
Gy x-ray radiation marginally increased after exposure, while the activity in devices 




Figure 37. Cytotoxicity due to x-ray radiation without HSPCs. Fold change in LDH 
released from hBM-on-a-chip (EC+MSC+OB) 24 hours post-x-ray irradiation compared 
to baseline (0 hours). Data are shown as mean ± SEM (n = 4 devices). Data analyzed using 
Kruskal-Wallis with Dunn’s multiple comparison test. No significance between groups (p 
< 0.1). 
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The change in cytokine secretion because of x-ray exposure was also measured. IL-
6, IL-7, IL-11, M-CSF, and SCF were detected, however CXCL12, IL-3, IL-15, IL-34, 
GM-CSF, FLT3L, and LIF were not above the detection limit of the assay. While there 
was no significant difference between the groups, it is worth noting that there was a 




Figure 38. Effect of radiation on cytokine secretion without HSPCs. Change in 
hematopoietic cytokine measured in hBM-on-a-chip (EC+MSC+OB) supernatant before 
(0 hours) and 24 hours after devices were exposed to 0 (white), 2.5 (light grey), 5 (grey), 
or 10 (dark grey) Gy x-ray radiation. Data are shown as mean ± SEM (n = 4 devices). Data 
analyzed using Kruskal-Wallis with Dunn’s multiple comparisons test.  
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Figure 39. Dose response of HSPCs to x-ray radiation. (A) Representative images of 
TUNEL (white) and CD45 (green) staining of devices exposed to 0, 2.5, 5, or 10 Gy 
radiation 24 hours after exposure. Scale bar: 50 µm. (B) Quantification of percentage of 
TUNEL+ CD45 cells 24 hours after 0 (white), 2.5 (light grey), 5 (grey), 10 dark grey) Gy 
radiation exposure shown by (i) ROI and (ii) device. Data (n = 15 ROIs (i) from 3 devices 
(ii)) are shown as mean ± SEM. Data analyzed using Kruskal-Wallis with Dunn’s multiple 
comparisons test. No significance between groups (p < 0.1). 
 
 
6.2.3 Fate of x-ray irradiated HSPCs 
 hBM-on-a-chip (EC+MSC+OB+HSPC) were irradiated after 5 days of 
vasculogenesis and the frequency of apoptotic cells 24 hours post exposure was quantified 
using a TUNEL assay (Figure 39). Because the hBM-on-a-chip is a co-culture, TUNEL 
staining was not restricted to HSPCs and many non-hematopoietic cells were observed 
staining positive for TUNEL (Figure 39A). The percentage of TUNEL+ HSPCs was 
relatively high, 19.7 ± 3.8%, in non-irradiated samples (Figure 39B), suggesting that there 
is a high rate of on-going apoptosis in the culture hematopoietic cells in hBM-on-a-chip. 
When exposed to x-ray radiation, there was not a statistically significant increase in 
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TUNEL+ HSPCs, however there was a trend of increased TUNEL+ HSPCs with increasing 
dose. HSPCs in hBM-on-a-chip irradiated with 2.5, 5, and 10 Gy radiation were TUNEL+ 




Figure 40. Role of endosteal niche in radiation damage to HSPCs.(A) Representative 
images of TUNEL (white) and CD45 (green) staining of devices, with or without OBs, 
exposed to 0 or 5 Gy radiation 24 hours after exposure. Scale bar: 50 µm. (B) 
Quantification of percentage of TUNEL+ CD45 cells, with (triangles) or without (circles) 
OBs, 24 hours after 0 (white) or 5 (grey) Gy radiation exposure shown by (i) ROI and (ii) 
device. Data are shown as mean ± SEM (n = 15 ROIs (i), n = 3 devices (ii)). Data analyzed 
using Kruskal-Wallis with Dunn’s multiple comparisons test. No significance between 
groups (p < 0.1). 
 
 
6.2.4 Effect of endosteal niche on x-ray irradiated HSPCs 
 After observing a relatively mild increase in apoptotic HSPCs after exposure to 
radiation doses upwards of 10 Gy, we sought to determine whether the presence of the 
endosteal niche was ameliorating the effects of radiation for HSPCs. hBM-on-a-chip with 
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(EC+MSC+OB+HSPC) and without (EC+MSC+HSPC) the endosteal niche, were exposed 
to 5 Gy x-ray radiation and again apoptosis was measured 24 hours after exposure via a 
TUNEL assay (Figure 40). Similarly, high backgrounds of apoptotic HSPCs were 
observed, 17.5 ± 0.1% of HSPCs in untreated -OB samples and 16.3 ± 2.8% of HSPCs in 
untreated +OB samples staining positive for TUNEL (Figure 40B). While, again, there was 
not a statistically significant difference between any of the groups, we saw a similar, 
moderate increase in TUNEL+ HSPCs in +OB devices exposed to 5 Gy radiation (17.7 ± 
2.0%). There was a larger increase in TUNEL+ HSPCs when exposed to 5 Gy radiation 
without the endosteal niche (-OB) present, with 22.6 ± 1.9% of HSPCs apoptotic.  
6.2.5 Post-irradiation treatment with G-CSF 
 After radiation injury, there are a number of countermeasures that are used to 
prevent failure of the hematopoietic system, including G-CSF [227]. To test G-CSFs ability 
to increase hematopoietic survival post-irradiation, we treated perivascular niche (-OB) 
and vascularized endosteal niche (+OB) hBM-on-a-chip with G-CSF (10 ng/mL) 24 hours 
after radiation exposure and then measured HSPC apoptosis at 48 hours by a TUNEL assay 
(Figure 41). Similarly to previous experiment, we measured a high background of TUNEL+ 
HSPCs and high variability between imaged ROIs (Figure 41i) and device replicates 
(Figure 41ii). While no differences between groups were statistically significant, there was 
a modest increase in TUNEL+ HSPCs in the perivascular niche (-OB) devices exposed to 
5 Gy radiation (19.1 ± 4.7%) when compared to non-irradiated samples (16.4 ± 2.7%) or 
irradiated devices treated with G-CSF (17.3 ± 2.3%). Likewise, there was a potential 
decrease in TUNEL+ HSPCs in irradiated vascularized endosteal niche devices treated with 
G-CSF (15.4 ± 2.8%) compared to irradiated samples that were untreated (17.9 ± 2.0%).  
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Figure 41. Post-irradiation treatment with G-CSF. Quantification of percentage of 
TUNEL+ CD45 cells at 48 hours after 0 (white) or 5 (grey) Gy radiation exposure, with 
(10 ng/mL) or without G-CSF treatment 24 hours post-irradiation, with (triangles) or 
without (circles) OBs shown by (i) ROI and (ii) device. Data are shown as mean ± SEM (n 
= 15-20 ROIs (i), n = 3-4 devices (ii)). Data analyzed using Kruskal-Wallis with Dunn’s 




6.3.1 Previously described methods 
hBM-on-chip were fabricated and cultured using the methods described in 
CHAPTER 3 and CHAPTER 4, see the following sections: 
3.3.3.3 Version 2.0 device fabrication 
3.3.5 Surface coating of PDMS 
4.3.2 Cell culture 
4.3.3 Osteogenesis in hBM-on-a-chip 
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4.3.5 Vasculogenesis in hBM-on-a-chip 
4.3.10 Culture of CD34+ BM HSPCs in hBM-on-a-chip 
6.3.2 Radiation dose measurement and PDMS attenuation 
Dosimeters (nanoDot™, Landauer) were exposed to theoretical radiation doses of 
2.5, 5, and 10 Gy using an RS 2000 X-Ray Irradiator (Rad Source) at 2.15 Gy/min. To 
determine x-ray attenuation by the PDMS in hBM-on-a-chip, dosimeters were placed 
underneath a well-plate hBM-on-a-chip during exposure. Control samples were exposed 
without PDMS device shielding. A transit control dosimeter was also measured and the 
background radiation dose during shipping and use was subtracted from all test dosimeters. 
Dosimeters were returned to the service provider (Landauer) for dose measurements. 
6.3.3 X-ray radiation of hBM-on-a-chip 
On day 5, hBM-on-a-chip devices were transported to an animal facility and 
exposed to ionizing radiation using an RS 2000 X-Ray Irradiator (Rad Source). To control 
for effects of transportation, untreated samples were also transported to the facility. The 
duration of the process (transportation to and from the facility and x-ray exposure) was ~1 
hour, during which time the samples were not held at 37 °C, 5% CO2. 
6.3.4 Lactate dehydrogenase assay to measure cytotoxicity 
Device supernatant was collected (0 hour), replaced prior to radiation exposure and 
collected 24 hours after exposure. Supernatant was flash frozen immediately upon 
collection and stored at -20 °C prior to analysis. LDH activity was measured using the 
Pierce™ LDH Cytotoxicity Assay (ThermoFisher) according to the manufacturer’s 
protocol. For each device, i, the 24-hour fold-change in LDH activity was calculated by 
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dividing the background subtracted A490 at 24 hours from the sample matched 0-hour value. 
6.3.5 Multiplex cytokine detection 
 Device media was collected at 0 hours (immediately prior to transport to radiation 
facility) and 24 hours after exposure. Media was collected from devices at designated time 
by collecting media from one side of device, waiting for 5 minutes to allow for gravity 
driven flow through the device and then collection of all media from reservoirs. Device 
media was immediately stored on ice and then flash frozen in liquid N2 for storage prior to 
analysis. Samples were thawed on ice prior to detection and analysis using LEGENDplex 
human hematopoietic stem cell panel (BioLegend), according to manufacturer’s protocol. 
6.3.6 TUNEL assay 
DNA damage to HSPCs was observed using terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick-end labelling (TUNEL) immunostaining (Click-iT TUNEL 
Alexa Fluor Assay Kit, ThermoFisher) according to the manufacturer’s protocol. Briefly, 
formaldehyde fixed devices were first permeabilized with Triton-X100 (Avocado). Next, 
terminal deoxynucleotidyl transferase (TdT) was used to incorporate dUTP into double 
stranded breaks of DNA. Alexa Fluor 647 azide was then bound to dUTP using click 
chemistry. As membrane stains of HSPCs do not survive Triton-X100 permeabilization, 
HSPCs were then stained overnight using anti-human CD45 Alexa Fluor 488 (BioLegend). 
Samples were imaged using a spinning disk confocal microscope (PerkinElmer) and 
images were analyzed using Volocity software (PerkinElmer). 
6.3.7 G-CSF treatment  
 Devices were exposed to x-ray radiation at indicated doses 5 days after initiation of 
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vasculogenesis. 24 hours after radiation exposure, media was removed and replaced with 
EGM-2MV (Lonza) supplemented with 10 ng/mL G-CSF (Peprotech). Devices were 
cultured at 37 ºC, 5% CO2 for an additional 24 hours after G-CSF treatment before being 
assayed (48 hours after radiation exposure). 
6.4 Discussion 
 Radiation is both an important clinical tool for the treatment of various 
malignancies and an acute health risk is accidental exposure situations. Within BM, 
understanding how the endosteal niche and the perivascular niche respond to radiation 
insult, and how this affects HSPC fate after radiation injury is important for understanding 
clinical outcomes and developing effective countermeasures that maintain the BM niche 
for HSPCs. Radiation of the BM microenvironment has largely been studied using animal 
models, but there are examples that use complex in vitro BM models [225].  
 Here, we investigated the effect of radiation on the BM microenvironment on hBM-
on-a-chip and the outcome on HSPCs located in the vascularized endosteal and 
perivascular niches. Unexpectedly, exposure to relatively high doses of x-ray radiation (up 
to 10 Gy) did not induce a significant increase in cell death in vascularized endosteal niche 
hBM-on-a-chip (EC+MSC+OB), as measured by LDH release. There was a corresponding 
decrease, although not statistically significant, in cytokine expression 24 hours after 
radiation exposure. This suggested that the expression and, subsequently, the BM niche 
were potentially altered, albeit without widespread apoptosis of stromal cells. HSPCs 
cultured in the vascularized endosteal niche (HSPC+EC+MSC+OB) similarly did not 
exhibit a significant increase in apoptosis 24 hours after exposure as measured by damage 
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to nuclear DNA (TUNEL). In comparison, we observed an increase, although not 
statistically significant, in TUNEL+ HSPCs in the perivascular niche (HSPC+EC+MSC) 
after 5 Gy radiation exposure. MSCs have been reported to be resistant to damage 
associated with radiation exposure [219] and given the greater number of MSC derived 
cells in OB containing devices, the density of these radio-resistant (and potentially radio 
protective) cells could be mitigating damage to HSPCs. Further study measuring the 
production of reactive oxygen species (ROS) after radiation exposure of the perivascular 
and vascularized endosteal niches may help explain the difference in HSPC outcome in 
these microenvironments.  
 Lack of change in LDH measurement and high background in the TUNEL assay 
made it difficult to make definitive conclusions regarding the application of hBM-on-a-
chip for the study of radiation damage. Other approaches will be required for further study 
that yields definitive results. Also, the high background of TUNEL+ HSPCs in hBM-on-a-
chip may be an indication that the microenvironment created in its current form may not 
suitable for long-term culture of HSPCs. Altering the media conditions, adding constant 




CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
In this dissertation, a novel approach to recapitulating both the endosteal and 
perivascular microenvironments of human BM was presented. Numerous approaches 
toward replicating the HSC niche of BM in vitro have been developed over several decades. 
Defined monocultures of HSCs with specific biochemical and physical cues, co-cultures 
with stromal cells that recreate basic niche interactions, and in vivo generated ectopic BM 
models have been presented as recreations of the HSC niche with vastly different levels of 
complexity. The hBM-on-a-chip culture system that we have presented here is one of few 
examples that integrate both the perivascular and endosteal niches entirely in vitro [103] 
and it is unique in its approach. The hBM-on-a-chip is a simple platform that recreates 
basic physiologic structures but could relatively easily be increased in complexity to 
accommodate further lines of investigation that require it.  
In Aim 1A, the fabrication of hBM-on-a-chip was improved from a relatively labor-
intensive process that was flexible and afforded optimization during early studies, to a 
simple and scalable process at a research laboratory scale. We have demonstrated that the 
microfluidic approach is easily adapted to a standard well-plate format that enables 
increased scale, ease of handling, and integration with laboratory instrumentation. We 
employed the well-plate hBM-on-a-chip in an automated imaging platform (BioSpa, 
BioTek) that uses mechanized systems to handle plates during imaging procedures over 
extended periods of time and allow for multiple plates to be automatically imaged in 
parallel. This overcomes a limitation of scalability of organ-on-a-chip platforms, especially 
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during early development. Using a well-plate format can also enable the use of additional 
automated systems, which could include instrumentation for automated liquid handling and 
cell culture. The loading and culture of these devices, using the techniques presented here, 
requires significant manual manipulation that requires expertise and, even with said 
expertise, can lead to significant variation between devices. Automation would not only 
decrease the labor required for the culture and maintenance of the hBM-on-a-chip, but it 
would also likely decrease the variation we have observed. 
In Aim 1B, we demonstrated that the basic characteristics of the endosteal and 
perivascular niches could be recreated in hBM-on-a-chip. Using MSCs, we differentiated 
an endosteal surface within the central channel of the device and were able to subsequently 
seed ECs and MSCs on top of the endosteal surface and form microvasculature. This 
approach is flexible – we demonstrated that we can create both a vascularized endosteal 
niche and a perivascular BM niche – and could likely be used to integrate any number of 
cell types into the device to achieve the desired microenvironment constituents. We found 
that HSPCs cultured in the presence of the endosteal niche proliferated less, but retained 
more expression of CD34, a potency marker, showing that the two microenvironments are 
functionally different in their interactions with HSPCs.  
In Aim 2A, we explored the application of hBM-on-a-chip for studying the 
mobilization of HSPCs from the BM microenvironment. While inconclusive, G-CSF may 
reduce the expression of CXCL12 in hBM-on-a-chip, consistent with observations in 
preclinical animal models [228]. G-CSF increased the length and displacement of HSPC 
migration, both in the vascularized endosteal niche and the perivascular niche of hBM-on-
a-chip, however this mobilization was not observed when the protease inhibitor bortezomib 
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was also used. This was a surprising result given the evidence that bortezomib alone can 
induce mobilization [210]. In one sense, this is encouraging that the hBM-on-a-chip can 
capture the interaction between two therapeutics, however it is also an indication that the 
hBM-on-a-chip is not fully recapitulating in vivo biology. The use of this platform for 
studying mobilization has potential, although further work is needed to better correlate in 
vitro results with animal and clinical data. 
In Aim 2B, we investigated the effects of radiation on hBM-on-a-chip and the 
resulting effects on HSPCs. We measured limited stromal cell death as a result of high 
doses of x-ray radiation, but this corresponded with a suspected decrease in cytokine 
secretion at higher doses that suggest the microenvironment is affected by the radiation 
exposure. Measurement of damage to HSPCs and resulting apoptosis via the TUNEL assay 
proved to be difficult and did not yield any statistically significant results. HSPCs cultured 
in perivascular niche (HSPC+EC+MSC) were potentially more sensitive to radiation 
exposure when compared to those cultured in the vascularized endosteal niche 
(HSPC+EC+MSC+OB). If this can be fleshed out further, this has implications for 
countermeasure approaches to accidental radiation exposure. Radioprotection may not be 
exclusive to HSPCs, if cancerous cells in BM are similarly protected in the endosteal niche 
it would have implications in the treatment of BM malignancies. 
Increased sample sizes may be required to gain meaningful and conclusive insights 
from radiation studies if the effect size and standard deviation observed in these studies 
holds true. If we take the effect of 5 Gy radiation compared to untreated samples measured 
in “perivascular niche” devices (-OB) as an example (Figure 40), we can perform a power 
analysis to determine the number of devices necessary to determine the effect size. 
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Assuming that α = 0.05, power = 0.80, mean of control is 17.5%, mean of 5 Gy is 22.5%, 
and the standard deviation of both populations is approximately 4%, the sample size needed 
in each group is 10. If this is an overly optimistic assumption of intra-device variability 
and the standard deviation of the population is actually 5%, sample size would increase to 
16 devices per group. However, if variance could be decreased to 3% through improved 
methods, the sample size required decreases to 6 devices per group. Increasing the sample 
size is necessary to observe the effect size that these studies have suggested is present, 
however decreasing the intra-device variability is also necessary for practical execution of 
these experiments. 
The hBM-on-a-chip developed in this dissertation recreates basic structures of 
human bone marrow and we have shown that it has potential applications in studying the 
HSPC BM niche in a controlled, human, in vitro culture platform.  
7.2 Future directions 
There are several directions that could be taken to improve upon the device design, 
fabrication, culture, and its applications in research. 
The use of PDMS materials, while flexible and useful for laboratory scale 
production of devices, have limited utility moving beyond basic research. The issues 
associated with PDMS absorption of small molecules could potentially be restrictive if the 
platform was used for further pharmacological studies. Fabricating the device layer from 
PDMS also results in slight variability in the height of the hBM-on-a-chip within a well-
plate, which can be problematic when imaging the devices in an automated fashion. The 
platform could be improved by removing PDMS from the device construction and using 
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polycarbonate or similar material that could be manufactured in a more controlled and 
scalable fashion. Using more controlled fabrication approaches would decrease this 
variability. 
Additionally, commercially available silicon films could (and should) replace the 
use of in-house made films to produce a more standard and consistent platform. Moving to 
commercially available PDMS films, while expensive, have the additional benefit of being 
packaged between two sheets of hard plastic. One sheet can be removed, allowing for the 
bonding of the PDMS to the device layer and the other can be maintained during culture. 
This would eliminate the need for coverslips to be bonded to the bottom of the devices to 
provide structural support during culture, reducing fabrication time and complexity. 
The process for culturing hBM-on-a-chip is time intensive. At 26 days from initial 
seeding of MSCs to having a vascularized hBM-on-a-chip, there is opportunity and 
necessity to decrease the culture time if the platform is going to be used in a clinical setting. 
The most apparent step for shortening is the differentiation of MSCs to osteoblasts. The 
current protocol is a standard differentiation protocol, however there are now 
differentiation media products that are commercially available that claim to shorten 
osteoblast differentiation time. The downside with these products is that the materials are 
proprietary, although the time of culture would be shortened, the mechanism of 
differentiation is unknown and the culture media itself is not fully defined for the user.  
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Figure 42. Blocking polydopamine and collagen coating with BSA. PDMS was (1) 
blocked with BSA (10 µg/mL), (2) coated with polydopamine (PDA) (100 µg/mL), and 
(3) coated with collagen 1 (100 µg/mL) and stained with picrosirius red to visualize 
collagen adsorption to the PDMS surface. 
 
 
One critical limitation of the device in its current design is the inability to generate 
consistently perfusable vasculature in the presence of OBs due to slight delamination of 
the fibrin-collagen hydrogel from the PDMS surface. Currently, the entire surface 
(including walls and top) of the central channel is coated with polydopamine and collagen 
I prior to MSC loading in the central channel. This coating is likely affecting the ability of 
the hydrogel to attach sufficiently to the PDMS surface downstream. One approach to 
mitigate this would be to exclusively coat the bottom surface of PDMS with polydopamine 
and collagen. This could be achieved through by (1) blocking the PDMS walls and top with 
BSA or another non-specific protein prior to device assembly, which would limit the 
adsorption of collagen to these surfaces (Figure 42). Alternatively, (2) the bottom surface 
of PDMS could be patterned with polydopamine and collagen coating prior to device 
assembly using a masking technique [229].  
There are several potential approaches to improving upon the method of 
vasculogenesis. Using MSCs or fibroblasts in the outer channels of the device to generate 
vasculogenic factors is poorly controlled, not defined, and is dependent on biological 
variability of the cells themselves (lot, passage number, etc.). Methods that use fluid shear 
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stress to induce vasculogenesis [172,177] allow for the development of microvasculature 
without added cytokine or stromal support. Adaptation of these methods would lead to a 
more defined hBM-on-a-chip and, because of the added fluid flow, may allow for increased 




Figure 43. Hypoxia in perivascular and vascularized endosteal niches. Z-projections 
of hBM-on-a-chip with and without OB stained with Image-iT Green Hypoxia Reagent 
(ThermoFisher) and cultured for 2 hours at 37 ºC, 5% CO2, 20% O2 prior to imaging. Scale 
bar: 50 µm. 
 
 
There are myriad additional studies that could be performed to further characterize 
the microenvironment that is being formed within the hBM-on-a-chip. The experiments in 
this dissertation were all performed under normal oxygen conditions (~20% O2), however 
the oxygen tension of BM is lower and variable through the tissue [50]. Because of the 
high cellularity of the device, we hypothesized that local hypoxic environments might be 
present. Using a fluorescent hypoxia reagent, we visualized the hypoxic microenvironment 
in the perivascular (-OB) and vascularized endosteal (+OB) niches (Figure 43). Preliminary 
results show a more diffuse hypoxic environment with OBs present and more local, but 
more intense hypoxia without OBs near vasculature and perivascular stromal cells. It is 
important to note that because the vasculature is not being constantly perfused with 
oxygenated media, like how vasculature is constantly supplied with blood, this observation 
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may be conflict with the hypoxic environment in vivo. Culture of hBM-on-a-chip in a range 
of hypoxic conditions would be interesting and could create unique HSPC niche 
characteristics. 
We characterized the proliferation and maintenance of multipotency (via CD34 
expression) of HSPCs, additional investigation into the differentiation of HSPCs would 
further define the BM microenvironment that is being created. If the goal is to create a 
representative BM microenvironment from HSPCs, culture times would need to be 
increased to allow for the differentiation of the milieu of cell types present in native tissue. 
Due to the slowdown in proliferation we measured within 5 days, different media 
compositions or fluid flow would likely need to be applied in order to generate the cellular 
density of BM tissue (if it is possible in this platform). 
Increasing the complexity of hBM-on-a-chip through the addition of additional BM 
cell types would additional nuance and accuracy to this model of BM. There are numerous 
cell types that are present in BM that were excluded from these studies, including 
macrophages, osteoclasts, adipocytes, neutrophils, and Schwann cells. Some of these cell 
types, like adipocytes, would be relatively easy to integrate into the existing methods, 
however, immune cells may be more difficult to incorporate into cultures where cell types 
are from multiple donors without HLA-matching.  
An interesting approach to creating a more complex BM-on-chip would be to use 
whole BM as the starting material. Potentially, stromal cells (MSCs, ECs, and OBs) could 
be isolated from the whole BM, at which point they could be introduced into the culture 
for differentiation (MSCs) or stored for subsequent seeding after endosteal formation. The 
advantageous to having single source material are many. Genetically, the cells would be 
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identical, this would remove any conflicting responses due to competing genotypes in the 
stromal cell subsets. A BM-on-a-chip from a single material source could have potential to 
be a truly patient-specific model that would allow for screening and testing on an individual 
level. Lastly, for studies that are focused on the immune response in the BM 
microenvironment (e.g. chimeric antigen receptor-T cell efficacy), having cells that are 
HLA matched is essential for decreasing the amount of non-specific activation and killing. 
While increasing the complexity of hBM-on-a-chip is attractive for better 
replicating the native microenvironment, it would also significantly increase the technical 
difficulties associated with creating and culturing devices with low relatively low 
variability. Cell types should be chosen carefully for their inclusion or exclusion from 
specific models in order to best mimic the least complex microenvironment necessary for 
modeling the physiologic state of interest. A deliberate and minimalist approach is more 
likely to lead to successful creation of BM microenvironment models and the collection of 
meaningful data. 
 The results we have gathered show that hBM-on-a-chip could be a potential tool 
for studying mobilization of HSPCs. The lack of G-CSF mobilization in the context of 
bortezomib treatment was unexpected. Additional studies looking at mobilization with 
concurrent chemotherapeutic treatment with thalidomide, lenalidomide, dexamethasone, 
and derivatives of cyclophosphamide would help us better understand the impact of 
chemotherapeutics on mobilization in hBM-on-a-chip. Given the uncertain data gathered 
for high dose AMD3100 treatment, further studies are warranted for the mobilization with 
the drug. There are a few agents that have been tested in preclinical situations, including 
S1P, Groβ, IL-8, and many more [204]. Screening of these drugs could elucidate which 
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mechanisms of action the hBM-on-a-chip may be appropriate for testing. 
Similarly, there are many potential therapeutics that could be screened for their 
potential as radiation countermeasures in hBM-on-a-chip if, as previously discussed, the 
sensitivity of measurements can be improved. Glutathione and bactericidal/permeability-
increasing protein [230] are potential therapeutics that could be tested in hBM-on-a-chip. 
Their relative efficacy in the perivascular and vascularized endosteal niche hBM-on-a-
chips could be informative for radiation countermeasure strategies by providing the 
microenvironment context of their efficacy. The effects of radiation on the hBM-on-a-chip 
microenvironment could also be further studied. If the perfusion of the devices become 
more consistent, experiments could be performed that measure the effect of radiation on 
the permeability of hBM-on-a-chip vasculature and the effect of specific stromal cells on 
mitigating or aggravating any response. Because restoration of blood flow to irradiated 
tissue is essential for functional recovery, these studies could be informative for designing 
small molecule or cell-based therapies that target the non-hematopoietic cells in BM in 
response to radiation insult. 
One apparent application of hBM-on-a-chip would be to use it as a tissue specific 
model of cancers that inhabit the BM. Multiple myeloma and leukemia, hematopoietic 
malignancies that occupy BM, are well reported to disrupt BM physiology, disrupting 
hematopoiesis and the immune system [231-234]. BM stromal cells and the BM 
microenvironment inevitably play a role in the progression and outcome of therapies that 
target these cancers. There are a number of examples of in vitro BM models that have been 
used to study the cancer microenvironment in BM [103,168]. The hBM-on-a-chip would 
be a novel in vitro tool for exploring how the endosteal and perivascular niches interact 
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with cancer cells and it could also serve as a physiologically relevant platform for testing 
the effectiveness of chemotherapeutics, radiation therapy, or cell-based cancer therapies 
(e.g. CAR-T cells). 
The culture method that we have described here has potential as a preclinical model 
that substitutes for traditional animal models. While it lacks the complexity of a whole, in 
vivo BM, using human cells in a relatively defined and tunable microenvironment has 
certain advantages. Additional work that further standardizes hBM-on-a-chip through 
updated design and fabrication, further characterizes the in vitro microenvironment, and 
adds additional complexity to the model are needed to create a robust, reliable, and higher 




APPENDIX A. DETAILED SOFT LITHOGRAPHY METHODS 
The fabrication of SU-8 master molds was done using the manufacturer’s protocol 
previously published methods. However, slight changes in the protocols were required to 
account or the specific instrumentation available and to achieve consistent, successful 
fabrication. 
A.1 Mask design 




Figure 44. Photomask design of device versions 1.0 and 1.1. Six, 5-channel hBM-on-a-
chip devices arranged in a 2x3 array for v1.0 and v1.1 fabrication. Guides are placed 
between devices for cutting of individual devices.  
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Figure 45. Photomask design of device version 2.0. Four, 5-channel hBM-on-a-chip 
devices arranged in a 2x2 array for version 2.0 fabrication. Guides are placed that align 





The coating of silicon wafers with SU-8 2150 generally followed the 
manufacturer’s protocol, however slight modifications were made that improved the 
adhesion of the SU-8 to the silicon surface and more reproducibly resulted in a successful 
fabrication process.  
A.2.1 Spin coating SU8 
Silicon wafers were cleaned with a solvent wash (acetone, methanol, isopropanol), 
dried with N2, and subsequently dehydrated on a hot plate at 200 °C for at least 5 minutes. 
Wafers were transferred to SCS G3P8 spin coater immediately prior to coating. To coat, 5 
mL room temperature SU-8 2150 was poured directly from the container (SU-8 2150 is 
too viscous to be aliquoted or pipetted directly) onto the center of the wafer and the wafer 
was immediately spun to coat the surface evenly (Table 4).   
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Table 4. SCS G3P8 protocol for spin coating SU-8 2150. 
Step Ramp (s) RPM Dwell (s) 
1 5 500 10 
2 10 2500* 30 
3 5 0 0 
 
 
 Coated wafers were immediately transferred to a 65 °C hotplate for 15 minutes. To 
avoid rapid change in temperature that can result in surface adhesion problems that are 
common with thick SU-8 coatings, the SU-8 coated wafers were then ramped up to 95 °C 
on the same hotplate and then held at 95 °C for 60 minutes. Similarly, after 60 minutes the 
hotplate was turned off and the wafers were cooled to room temperature on the hotplate 
surface over ~1 hour.  
A.2.2 UV exposure and development 
Once the SU-8 coated wafers had cooled to room temperature, the coated parts were 
transferred to the 100 mm chuck of the Suss Microtec MJB4 mask aligner. The intensity 
of the UV light source was measured, and an exposure time was calculated that would yield 






 Coated wafers were exposed through soda-lime or transparency mask and then 
immediately transferred to 65 °C hotplate and held for 5 minutes. Again, to avoid rapid 
changes in temperature, exposed wafers were kept on the hotplate and the temperature was 
adjusted to 95 °C. Exposed wafers were held at 95 °C for 15 minutes after which the 
                                                 
*Spin speed will vary depending on the age of the SU-8. Viscosity will increase over time 
as solvent evaporates and higher spin speeds will be required to achieve the same thickness. 
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hotplate was turned off and the wafers cooled to room temperature. Uncrosslinked SU-8 
was then removed using SU-8 developer. If after development, small adhesion problems 
had occurred, wafers were then hard baked by quickly transferring the wafer from 65 °C, 
to 95 °C, and 200 °C hotplates, holding for 1 minute at each temperature and then in reverse 
to come back to room temperature. 
A.2.3 Profilometry 
 The height of the fabricated SU-8 features were measured using a Dektak contact 
profilometer. Wafers with features were transferred to the profilometer platform. A feature 
in the center of the wafer, typically a cut or alignment guide, was chosen for measurement. 
The average step height (ASH) between the wafer and the feature was recorded.  
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APPENDIX B. QUANTIFICATION OF CXCL12 EXPRESSION 
CXCL12 was not detectable in the supernatant of hBM-on-a-chip using bead-based 
multiplex cytokine detection assays (Figure 19, Figure 20, Figure 24, Figure 26, Figure 
38), ELISA (not shown), or a modified ELISA assay that expands the detection range of 
analyte detection (not shown) [235]. Therefore, to measure relative changes in CXCL12 
expression, we used immunohistochemistry and quantification of fluorescence signal. 
B.1 Methods 
B.1.1 Immunohistochemistry staining 
Prior to fixation, positive control devices were treated with CXCL12 (Peprotech) 
by exchanging media with EBM-2MV supplemented with 1 ng/mL CXCL12. Devices 
were incubated for 30 minutes with CXCL12 supplemented media and then fixed with 
formaldehyde. 
Staining procedure for devices was adapted from Chen et al 2017 [170]. Devices 
were washed with PBS, fixed with 4% formaldehyde (ThermoFisher), and permeabilized 
with 0.1% Triton X-100. Prior to staining, cells were blocked with 5% BSA, 3% goat serum 
in PBS. Primary antibody was diluted (1:100) in blocking buffer and devices were stained 
overnight at 4 ºC. Devices were then washed with 0.1% BSA in PBS (wash buffer) and 
stained with secondary antibodies (1:200) diluted in wash buffer for 3 hours at RT. Devices 
were washed with wash buffer and with Phalloidin AF647 (1:40).  
B.1.2 Imaging and image analysis 
Stained hBM-on-a-chip devices were imaged using a spinning disk confocal 
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microscope (PerkinElmer). Five ROIs were imaged in each device in an evenly distributed 
array through the middle of the central channel (Figure 46). At each ROI, a 100 µm z-stack 




Figure 46. ROIs for CXCL12 imaging. Images were acquired at evenly spaced intervals 
in consistent locations. 
 
 
Images were processed and analyzed using open-source ImageJ software 
[130,131]. Images were background subtracted and had outliers removed prior to z-
projections being made using max intensity. CXCL12 expression was measured using the 
MFI of the GFP channel. 
B.2 Results 
 IHC staining showed CXCL12 expression by endothelial cells and perivascular 
stromal cells. In order to quantify the expression of CXCL12, we first needed to determine 
an appropriate method for image processing would eliminate nonspecific signal. Without 
processing (Figure 47A), the raw images indicated showed little to no signal without a 
primary antibody, however when an isotype control was used, there were nonspecific 
punctate signals observed. This same noise can be seen with an anti-CXCL12 antibody, 
and, although there is clearly a difference in specific staining, there is little differentiation 
between samples when measuring MFI (Figure 47B). 
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Figure 47. Measuring CXCL12 by IHC. (A) Z-projections created using maximum 
intensity and (B) quantification of MFI. (C) Background subtracted z-projections and (D) 
quantification of MFI. (E) Background subtracted, outlier removed z-projections and (F) 
quantification of MFI. Scale bar: 50 µm. Data (n = 5-10 ROIs from 1-2 devices) are shown 
as mean ± SEM. 
 
 
 Subtracting background from the images increased the signal-to-noise ratio, 
however it did not remove the punctate noise from the isotype or anti-CXCL12 samples 
(Figure 47C, D). Removing outliers from the images successfully removed the punctate 
noise (Figure 47E) and resulted in greater separation between the MFI of isotype and anti-
CXCL12 samples (Figure 47F).  
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APPENDIX C. DETAILED LIST OF MATERIALS 
Table 5. Antibodies and dilutions. 
Name Supplier Catalog No. Dilution (Conc.) 
Rabbit Anti-CXCL2 Abcam ab9797 1:100 (5 µg/mL) 
Rabbit Anti-Fibronectin Abcam Ab2413 1:100 (10 µg/mL) 
Rabbit Anti-JAG1 Abcam ab7771 1:100 (10 µg/mL) 
Rabbit Anti-Osteopontin Abcam ab8448 1:100 (82 µg/mL) 
Rabbit Anti-SCF Abcam ab64677 1:100 (10 µg/mL) 
Rabbit IgG Isotype Abcam ab37415 1:1000 (5 µg/mL) 
Anti-CD31 AF647 BioLegend 303112 1:100 (1 µg/mL) 
Anti-CD34 BV421 BioLegend 343609 1:100 (1 µg/mL) 
Anti-CD38 BV510 BioLegend 303539 1:100 (1.5 µg/mL) 
Anti-CD45 AF488 BioLegend 304019 1:100 (2 µg/mL) 
Anti-CD45RA AF647 BioLegend 304153 1:50 (1 µg/mL) 
Mouse IgG Isotype AF647 BioLegend 400330 1:500 (1 µg/mL) 
Mouse IgG Isotype BV 510 BioLegend 400171 1:67 (1.5 µg/mL) 
Mouse IgG Isotype BV421 BioLegend 400259 1:50 (1 µg/mL) 
Goat Anti-Rabbit AF488 Life Technologies A11008 1:200 (10 µg/mL) 
 
 
Table 6. Primary cells. 
Name Supplier Catalog Number Lot(s) 
BM CD34+ Cells Lonza 2M-101 0000690910 
0000573128 
HUVEC Lonza C2519A 0000470896 




Table 7. Detailed list of materials. 
Category Name Supplier Catalog Number(s) 
Chemical β-Glycerophosphate Sigma-Aldrich G9422 
Chemical (3-mercaptopropyl) trimethoxy silane Sigma-Aldrich 175617 
Chemical Alizarin Red S Sigma-Aldrich A553325G 
Chemical AMD3100 Sigma-Aldrich A5602 
Chemical Bortezomib Sigma-Aldrich 5043140001 
Chemical Bovine gelatin Sigma-Aldrich G9391 
Chemical Bovine serum albumin Sigma-Aldrich A2153 
Chemical Dexamethasone Sigma-Aldrich D2915 
Chemical Dopamine hydrochloride Sigma-Aldrich H8502 
Chemical Glycosil Hyaluronic Acid ESI Bio GS222 
Chemical Goat serum ThermoFisher 10000C 
Chemical Image-iT Green Hypoxia Reagent ThermoFisher I14833 
Chemical L-Ascorbic Acid Sigma-Aldrich 255564 
Chemical PEGDA Alfa Aesar AA4649703 
Chemical PKH67 Sigma-Aldrich MIDI67 
Chemical Rat Tail Collagen I Corning 354249 
Chemical Silver Nitrate Acros Organics 197680250 
Chemical Sodium Thiosulfate Acros Organics 202870010 
Chemical Trichloro (1H,1H,2H,2H-perfluorooctyl) silane Sigma-Aldrich 448931 
Chemical Triton X-100 Avocado A16046 
Cytokine Human Ang-1 PeproTech 130-06 
Cytokine Human CXCL12 Abcam ab9798 
Cytokine Human G-CSF PeproTech 300-23 
Cytokine Human SCF PeproTech 300-07 
Cytokine Human TPO PeproTech 300-18 
Cytokine Human VEGF PeproTech 100-20 
Kit Click-iT TUNEL Alexa Fluor 647 Imaging Assay ThermoFisher C10247 
Kit CXCL12 ELISA PeproTech 900-M92 
Kit IL-6 ELISA PeproTech 900-TM16 
Kit LDH Cytotoxicity Assay Kit ThermoFisher C20301 
Kit LEGENDplex Human HSC Panel BioLegend 740611 
Kit  SCF ELISA PeproTech 900-TM34 
Material 96-Well No-Bottom Plates Greiner Bio-One 655000-06 
Material 96-Well Plate Lids Greiner Bio-One 656170 
Material Silicon Wafer University Wafer 452 
Material Smooth-Cast 310 Smooth On N/A 
Material SU-8 2150 MicroChem NC0216470 
Material SU-8 Developer MicroChem NC9901158 
Material Sylgard 184 Silicone Elastomer Kit Dow Corning 2065622 
Media αMEM Sigma-Aldrich M0644 
Media EBM-2MV Lonza CC-3202 
Media FBS HyClone SH3007103 
Media Penicillin-Streptomycin HyClone SV30010 
Misc. Biopsy Punches Integra Miltex 33-31AA-P/25,  
33-31-P/25, 
33-34-P/25 
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